Supporting Information

Aromatization-driven deconstructive functionalization of spiro

dihydroquinazolinones via dual photoredox/nickel catalysis

Hong-Jie Miao, Jin-Hua Zhang, Wenke Li, Wenpeng Yang, Hong Xin, Pin Gao, Xin-Hua Duan and Li-Na ${\rm Guo}^*$

Department of Chemistry, School of Chemistry, Xi'an Key Laboratory of Sustainable Energy Material Chemistry and Engineering Research Center of Energy Storage Materials and Devices, Ministry of Education, Xi'an Jiaotong University, Xi'an 710049, China.

*E-mail: guoln81@xjtu.edu.cn

Table of Contents

1. General Information	S3
2. General Procedures	S4
2.1 General Procedure 1: Synthesis of Dihydroquinazolinones 1	S4
2.2 General Procedure 2: Synthesis of Alkynyl Bromide 2t	S4
2.3 General Procedure 3: Synthesis of Aryl Bromides 2w-2z	S5
2.4 General Procedure 4: Synthesis of 4CzIPN	S6
3. Optimization of Reaction Conditions	S 8
3.1 General Procedure for Photoredox Nickel-Catalyzed Coupling of	S 8
Dihydroquinazolinone 1a with 2a	
3.2 Optimization of Reaction Conditions	S 8
3.3 Respective Procedure for Photoredox Nickel-Catalyzed Coupling of	S12
Dihydroquinazolinone 1 with Bromides 2 or 4	
4. Gram-scale Synthesis	S13
5. Diverse Derivatizations of 3a or 3b	S14
6. Two-step Telescoping Procedure for the Formation of 3a	S17
7. Investigation of the Reaction Mechanism	S18
7.1 Active Ni(II)-Complex Species Experiment	S18
7.2 Radical Trapping and Inhibiting Experiments	S19
7.3 Radical Clock Experiment	S20
7.4 Steady-State Stern-Volmer Quenching Experiment	S20
7.5 Light on-off Experiments	S22
7.6 Cyclic Voltammetry Analysis	S22
8. Characterization of Starting Materials and Dihydroquinazolinones 1	S23
9. Characterization of Products	S27
10. References	S40
11. ¹ H NMR and ¹³ C NMR Spectra of Starting Materials and Products	S41

1. General Information

The reactions were conducted in oven-dried Schlenk-tube. And the photoinduced reactions were carried out in oven-dried Schlenk-tube with Wattecs blue LEDs Irradiation Parallel Reactor. Unless otherwise stated, all reagents were purchased from commercial sources and used without further purification. ¹H and ¹³C NMR spectra were recorded on a 400 MHz JEOL (100 MHz for ¹³C NMR) spectrometer at ambient temperature. Chemical shift is reported in ppm from TMS with the solvent resonance as internal standard (CDCl₃: ¹H NMR: δ 7.26; ¹³C NMR: δ 77.0). Coupling constants are reported in Hz with multiplicities denoted as s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), td (triplet of doublets) and m (multiplet). HRMS were obtained on a WATERS I-Class VION IMS Q-Tof. Melting points were measured using open glass capillaries in an SGW® X-4A apparatus. Analytical TLC: aluminum backed plates pre-coated (0.25 mm) with Merck Silica Gel 60F-254. Compounds were visualized by exposure to UV-light or by dipping the plates in 2,4-dinitrophenylhydrazine stain followed by heating.

2. General Procedures

2.1 General procedure 1: Synthesis of Dihydroquinazolinones 1¹



Dihydroquinazolinones 1 were prepared according to the literature. A 50 mL oven-dried roundbottom flask equipped with a magnetic stirrer was charged with 2-aminobenzamide (10 mmol, 1.0 equiv), corresponding cyclic ketone (11 mmol, 1.1 equiv) and Cp_2TiCl_2 (1 mol%) were dissolved in 10 mL EtOH in one portion under air. The reaction mixture was stirred at 50-80 °C until the reaction was completed as indicated by TLC. For compounds **1b-1d**, **1h-1l**: Upon completion of the reaction, the reaction mixture was quenched with distilled water. The resulting mixture was extracted with EtOAc (3×10 mL), and the combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography (PE/EtOAc = 2/1). For compounds **1a**, **1e**, **1f-1g**, **1m-1p**: The reaction was cooled to 20 °C generating precipitate that was collected as crude product by suction filtration. The crude material was washed with water and purified by recrystallization (EtOH) to give desired product.



Figure S1. Dihydroquinazolinones 1

2.2 General Procedure 2: Synthesis of Alkynyl Bromide 2t²

NC
$$\longrightarrow$$
 MeCN, rt, N₂ NC \longrightarrow Br

Charge a dried Schlenk flask equipped with a stir bar with ethynylbenzene (5.0 mmol, 1.0 equiv) in dry acetone. Evacuate the Schlenk flask. Fill the Schlenk flask with nitrogen (three cycles). Add AgNO₃ (0.5 mmol, 0.1 equiv), NBS (5.5 mmol, 1.1 equiv) in portions under the N₂ atmosphere to the above mixture. Stir the mixture for 7 h at room temperature. Monitor the completion of the reaction by TLC. Concentrate the solvent in vacuum. Dilute the reaction mixture with water. Extract the mixture with EtOAc. Dry the combined organic layer over Na₂SO₄. Filter the mixture. Concentrate the mixture to obtain the crude material. Purify the crude material by column chromatography (PE/ EtOAc = 50/1) to obtain alkynyl bromide **2t** as a white solid (0.8 g, 78%).

2.3 General Procedure 3: Synthesis of Aryl Bromides 2w-z³



To an oven-dried 50 mL round bottom flask equipped with a stir bar was added *L*-Menthol (5.0 mmol, 1.0 equiv), 4-bromobenzoic acid (6.0 mmol, 1.2 equiv), DCC (6.0 mmol, 1.2 equiv) and DCM (10 mL). And the reaction mixture was stirred at room temperature for 3 h. Monitor the completion of the reaction by TLC. Then, the reaction mixture was diluted with EtOAc and washed with brine solution. The organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE/ EtOAc = 20/1) to afford desired product **2v** as a colorless oil (1.4 g, 82%).



To an oven-dried 50 mL round bottom flask equipped with a stir bar was added diacetonefructose (5.0 mmol, 1.0 equiv), 4-bromobenzoic acid (6.0 mmol, 1.2 equiv), DCC (6.0 mmol, 1.2 equiv) and DCM (10 mL). And the reaction mixture was stirred at room temperature for 3 h. Monitor the completion of the reaction by TLC. Then, the reaction mixture was diluted with EtOAc and washed with brine solution. The organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE/ EtOAc = 20/1) to afford desired product **2w** as a white solid (1.6 g, 72% yield).



To an oven-dried 50 mL round bottom flask equipped with a stir bar was added Sitagliptin (2.0 mmol, 1.0 equiv), 4-bromobenzenesulfonyl chloride (2.2 mmol, 1.1 equiv), Et₃N (6.0 mmol, 3.0

equiv) and DCM (10 mL). And the reaction mixture was stirred at room temperature for 1 h. Monitor the completion of the reaction by TLC. Then, the reaction mixture was diluted with EtOAc and washed with brine solution. The organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE/ EtOAc = 1/1) to afford desired product **2x** as a white soild (0.8 g, 64%).



To an oven-dried 50 mL round bottom flask equipped with a stir bar was added Alogliptin (2.0 mmol, 1.0 equiv), 4-bromobenzenesulfonyl chloride (2.2 mmol, 1.1 equiv), Et₃N (6.0 mmol, 3.0 equiv) and DCM (10 mL). And the reaction mixture was stirred at room temperature for 1 h. Monitor the completion of the reaction by TLC. Then, the reaction mixture was diluted with EtOAc and washed with brine solution. The organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE/EA = 1:1) to afford desired product **2y** as a white soild (0.9 g, 81%).



To an oven-dried 50 mL round bottom flask equipped with a stir bar was added (+)-Dehydroabietylamine (2.0 mmol, 1.0 equiv), 4-bromobenzenesulfonyl chloride (2.2 mmol, 1.1 equiv), Et₃N (6.0 mmol, 3.0 equiv) and DCM (10 mL). And the reaction mixture was stirred at room temperature for 1 h. Monitor the completion of the reaction by TLC. Then, the reaction mixture was diluted with EtOAc and washed with brine solution. The organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography (PE/EtOAc = 1/1) to afford desired product as a white soild (0.5 g, 50%).

2.4 General Procedure 4: Synthesis of 4CzIPN⁴



NaH (60% in oil, 15.0 mmol, 1.5 equiv) was added slowly to a stirred solution of carbazole (10.0 mmol, 1.0 equiv) in dry THF (40 mL) under argon at room temperature. After 30 min, tetrafluoroisophthalonitrile (2.0 mmol, 0.2 equiv) was added. After stirring at room temperature for 12 h, 2 mL H₂O was added to the reaction mixture to quench the excess NaH. The resulting mixture was then concentrated under reduced pressure and washed by H_2O and EtOH to yield the crude

product, which was purified by recrystallization from acetone/CHCl₃ to give the product 4CzIPN (1.51 g, 96%).

3. Optimization of Reaction Conditions

3.1 General Procedure for Photoredox Nickel-Catalyzed Coupling of Dihydroquinazolinone 1a with Aryl Bromide 2a

To a 10 mL oven-dried Schlenk tube equipped with a magnetic stirrer was added PC (1 mol%), nickle catalyst (10 mol%), L (12 mol%) and Base (0.2 mmol, 1.0 equiv). Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of **1a** (0.3 mmol, 1.5 equiv) and **2a** (0.2 mmol, 1.0 equiv) in solvent (2 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. The reaction mixture was quenched with brine (10 mL) and extracted with EtOAc (3×5 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by flash column chromatography (PE/EtOAc = 3/1) on silica gel to afford compound **3a**.

Ac

3.2 Optimization of Reaction Conditions

Screening of Catalysts^a

NH Me NH H	+ + + Ac Hard Hard Hard Hard Hard Hard Hard Hard	$\stackrel{(\%)}{\xrightarrow{()}} \qquad $
Entry	Catalyst	Yield/% ^b
1	NiCl ₂ ·DME	73
2	NiCl ₂ ·6H ₂ O	45
3	Ni(dppe)Cl ₂	52
4	Ni(dppp)Cl ₂	40
5	Ni(PPh ₃)Cl ₂	69
6	Ni(NO ₃)·6H ₂ O	24
7	Ni(OTf) ₂	10
8	NiBr ₂	37
9	Ni(COD) ₂	18
10	Ni(dtbpy)Br ₂	70^c

^{*a*}Reaction conditions: **1a** (0.24 mmol, 1.2 equiv), **2a** (0.2 mmol, 1.0 equiv), 4CzIPN (1 mol%), Ni catalyst (10 mol%), **L2** (12 mol%), Na₂CO₃ (1.0 equiv), DMF (2 mL), 10 W blue LEDs irradiation at room temperature for 12 h under N₂. ^{*b*}Isolated yields. ^{*c*}No addition ligand.



^{*a*}Reaction conditions: **1a** (0.24 mmol, 1.2 equiv), **2a** (0.2 mmol, 1.0 equiv), 4CzIPN (1 mol%), NiCl₂·DME (10 mol%), L (12 mol%), Na₂CO₃ (1.0 equiv), DMF (2 mL), 10 W blue LEDs irradiation at room temperature for 12 h under N₂. ^{*b*}Isolated yields.

NH Me NH H +	Br	4CzIPN (1.0 mol%) NiCl ₂ •DME (10 mol%) L2 (12 mol%) Na ₂ CO ₃ (1.0 equiv) solvent, rt, N ₂ , blue LED	Ac NH Me
1a	2a		3a
Entry		Solvent	Yield/% ^b
1	I	DMF	73
2		DMAc	71
3		DMSO	81
4		NMP	68
5		MeCN	46
6		Acetone	59
7		МеОН	N.D.

^{*a*}Reaction conditions: **1a** (0.24 mmol, 1.2 equiv), **2a** (0.2 mmol, 1.0 equiv), PC (1 mol%), NiCl₂·DME (10 mol%), L**2** (12 mol%), Na₂CO₃ (1.0 equiv), and solvent (2 mL), 10 W blue LEDs irradiation at room temperature for 12 h under N₂. ^{*b*}Isolated yields. *Screening of PC*^{*a*}

NH Me NH H 1a	Br PC (1.0 mol%) NiCl₂•DME (10 mol%) L2 (12 mol%) Na₂CO₃ (1.0 equiv) DMSO, rt, N₂ 10 W blue LEDs (455 nm)	Ac NH Me 3a
Entry	PC	Yield/% ^b
1	4CzIPN	81
2	4CzPN	75
3	4CzTPN	67
4	Rhodamine B	trace
5	TPP	36
6	Ir[dF(CF ₃)ppy] ₂ (dtbpy)PF ₆	66

^{*a*}Reaction conditions: **1a** (0.24 mmol, 1.2 equiv), **2a** (0.2 mmol, 1.0 equiv), PC (1 mol%), NiCl₂·DME (10 mol%), L**2** (12 mol%), Na₂CO₃ (1.0 equiv), DMSO (2 mL), 10 W blue LEDs irradiation at room temperature for 12 h under N₂. ^{*b*}Isolated yields.

NH Me NH + 1a	Br Ac 2a	4CzIPN (1.0 mol%) NiCl₂•DME (10 mol%) L2 (12 mol%) Base (1.0 equiv) DMSO, rt, N₂ 10W blue LEDs (455 nm)	Ac NH Me 3a
Entry	_	Base	Yield/% ^b
1	-1	Na ₂ CO ₃	81
2		NaHCO ₃	63
3		K ₃ PO ₄	26
4		K ₂ CO ₃	83
5		Cs ₂ CO ₃	77
6		'BuOK	64
7		DIPEA	42
8		Et ₃ N	49
9		DABCO	trace
10		2,4,6-colidine	80

^{*a*}Reaction conditions: **1a** (0.24 mmol, 1.2 equiv), **2a** (0.2 mmol, 1.0 equiv), 4CzIPN (1 mol%), NiCl₂·DME (10 mol%), L2 (12 mol%), base (1.0 equiv), DMSO (2 mL), 10 W blue LEDs irradiation at room temperature for 12 h under N₂. ^{*b*}Isolated yields. *Ratio of 1a and 2a*^{*a*}

NH Me H 1a	Br Ac 2a	4CzIPN (1.0 mol%) NiCl ₂ •DME (10 mol%) L2 (12 mol%) K ₂ CO ₃ (1.0 equiv) DMSO, rt, N ₂ 10W blue LEDs (455nm)	Ac NH Me 3a
entry		1a (x equiv)	Yield/% ^b
1		1.0	65
2		1.2	83
3		1.5	90
4		1.8	88

^{*a*}Reaction conditions: **1a** (x equiv), **2a** (0.2 mmol, 1.0 equiv), 4CzIPN (1 mol%), NiCl₂·DME (10 mol%), **L2** (12 mol%), K₂CO₃ (1.0 equiv), DMSO (2 mL), 10 W blue LEDs irradiation at room temperature for 12 h under N₂. ^{*b*}Isolated yields.

NH Me H 1a	Br HC2IPN (1.0 mol%) NiCl ₂ •DME (10 mol%) L2 (12 mol%) K ₂ CO ₃ (1.0 equiv) DMSO, rt, N ₂ 10 W blue LEDs (455nm)	Ac NH Me 3a
entry	Variation	Yield/% ^b
1	none	90
2	w/o 4CzIPN	0
3	w/o NiCl2•DME	0
4	w/o L2	0
5	w/o light	0
6	w/o base	0
7	Under air	0

^{*a*}Reaction conditions: **1a** (0.3 mmol, 1.5 equiv), **2a** (0.2 mmol, 1.0 equiv), 4CzIPN (1 mol%), NiCl₂·DME (10 mol%), L**2** (12 mol%), K₂CO₃ (1.0 equiv), DMSO (2 mL), 10 W blue LEDs irradiation at room temperature for 12 h under N₂. ^{*b*}Isolated yields.

3.3 Respective Procedure for Photoredox Nickel-Catalyzed Coupling of Dihydroquinazolinone 1 with Bromides 2 or 4

To a 10 mL oven-dried Schlenk tube equipped with a magnetic stirrer was added 4CzIPN (1 mol%), NiCl₂•DME (10 mol%), L2 (12 mol%) and K₂CO₃ (0.2 mmol, 1.0 equiv). Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of 1 (0.3 mmol, 1.5 equiv) and 2 or 4 (0.2 mmol, 1.0 equiv) in DMSO (2 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. The reaction mixture was quenched with brine (10 mL) and extracted with EtOAc (3×5 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by flash column chromatography (PE/EtOAc = 3/1) on silica gel to afford compound 3, 5 and 6.

4. Scale-up Synthesis



To a 100 mL oven-dried Schlenk tube equipped with a magnetic stirrer was added 4CzIPN (1 mol%), NiCl₂•DME (10 mol%), L2 (12 mol%) and K₂CO₃ (5 mmol, 1.0 equiv). Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of **1a** (7.5 mmol, 1.5 equiv), **2a** (5.0 mmol, 1.0 equiv) in DMSO (50 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with10 W blue LEDs at room temperature for 12 h. The reaction mixture was quenched with brine (20 mL) and extracted with EtOAc (3×10 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by flash column chromatography (PE/EtOAc =3/1) on silica gel to afford compound **3a** as a white solid (1.2 g, 72% yield).

5. Diverse Derivatizations of 3a or 3b⁵



To a 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was added **3a** (0.2 mmol, 1.0 equiv) and K_2CO_3 (0.4 mmol, 2.0 equiv). Subsequently, a solution of 2,4-dinitrofluorobenzene (0.24 mmol, 1.2 equiv) in MeCN (2 mL) was added by syringe. The resulting mixture was stirred at 80 °C for 6 h, and then the reaction mixture was directly subjected to flash column chromatography on silica gel (PE/EA = 4/1) to afford the corresponding product **7a** as a yellow oil (63.8 mg, 64% yield).



2-(4-(4-Acetylphenyl)pentyl)-3-(2,4-dinitrophenyl)quinazolin-4(3H)-one (7**a**): Yellow oil (63.8 mg, 64% yield); $R_f = 0.2$ (PE/EtOAc = 4/1); ¹**H NMR** (400 MHz, CDCl₃) δ 8.98 (s, 1H), 8.54 (d, J = 8.8 Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 7.96-7.90 (m, 2H), 7.85 (d, J = 8.4 Hz, 2H), 7.67-7.64 (m, 2H), 7.21 (d, J = 8.0 Hz, 2H), 2.78-2.72 (m, 3H), 2.58 (s, 3H), 1.66-1.49 (m, 4H), 1.20 (d, J = 7.2 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃) δ 197.9, 165.8, 164.8, 153.2, 152.5, 150.2, 144.8, 142.3, 135.1, 134.8, 128.9, 128.5, 127.5, 127.4, 127.2, 126.6, 123.1, 121.6, 113.5, 39.9, 39.0, 37.4, 26.5, 26.1, 21.9 ppm; **HRMS** (ESI) calcd for C₂₇H₂₅N₄O₆ [M+H]⁺ 501.1769, found 501.1775.



To a 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was added **3a** (0.2 mmol, 1.0 equiv), Morita–Baylis–Hillman carbonates (0.24 mmol, 1.2 equiv) and DABCO (0.04 mmol, 0.2 equiv). Subsequently, MeCN (2 mL) was added by syringe. The resulting mixture was stirred at room temperature for 3 h, and then the reaction mixture was directly subjected to flash column chromatography on silica gel (PE/EA = 4/1) to afford the product **8a** as a colorless oil (89.5 mg, 88% yield, d.r. = 1:1).



Methyl 2-((2-(4-(4-acetylphenyl)pentyl)-4-oxoquinazolin-3(4H)-yl)(phenyl)methyl)acrylate (8a): Colorless oil (89.5 mg, 88% yield); $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, J = 8.0 Hz, 1H), 7.85 (m, 2H), 7.72-7.68 (m, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.42-7.38 (m, 1H), 7.34-7.27 (m, 3H), 7.22-7.20 (m, 4H), 6.79-6.64 (m, 1H), 6.54 (m, 1H), 5.63 (dd, J = 5.6 Hz, 1.6 Hz, 1H), 3.694 (s, 1.5H), 3.690 (s, 1.5H), 2.87-2.65 (m, 3H), 2.57 (s, 1.5H), 2.56 (s, 1.5H), 1.70-1.60 (m, 4H), 1.22-1.19 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 166.4, 162.5, 157.2, 152.91, 152.87, 146.8, 137.93, 137.88, 136.6, 135.1, 134.2, 128.9, 128.6, 128.5, 127.8, 127.1, 126.8, 126.7, 126.4, 121.1, 52.2, 39.84, 39.78, 37.4, 37.3, 35.8, 26.5, 25.1, 25.0, 21.9, 21.8 ppm; HRMS (ESI) calcd for C₃₂H₃₃N₂O₄ [M+H]⁺ 509.2435, found 509.2437.



To a 5 mL glass tube with magnetic stirring bar was added **3b** (0.2 mmol, 1.0 equiv), benzylamine (0.3 mmol, 1.5 equiv), hexamethyldisilazane (0.56 mmol, 1.5 equv.) and $(NH_4)_2SO_4$ (0.02 mmol, 10 mol%). Place the tub in an oil bath. Pre-heat the tube to 125 °C. Stir the mixture for 3 h. After completion of the reaction, the reaction mixture was cooled to room temperature. Dilute the reaction mixture with CH₂Cl₂ and purify by flash column chromatography on silica gel (PE/EA = 1/1) to afford the corresponding product **9a** (77.2 mg, 84% yield).



N-Benzyl-2-(4-(4-(methylsulfonyl)phenyl)pentyl)quinazolin-4-amine (9a): colorless oil (77.2 mg, 84% yield); $R_f = 0.2$ (PE/EA = 1:1); ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.68-7.64 (m, 1H), 7.37-7.28 (m, 8H), 6.27 (t, J = 5.2 Hz, 1H), 4.87-4.78 (m, 2H), 2.97 (s, 3H), 2.86-2.81 (m, 3H), 1.87-1.64 (m, 4H), 1.23 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 167.0, 159.3, 154.3, 149.9, 138.6, 137.7, 132.4, 128.6, 128.0, 127.9, 127.7, 127.5, 127.3, 125.1, 120.6, 113.1, 44.8, 44.5, 39.9, 39.7, 37.6, 26.4, 21.9 ppm; HRMS (ESI) calcd for C₂₇H₃₀N₃O₂S [M+H]⁺ 460.2053, found 460.2057.



A solution of **3a** (0.20 mmol, 1.0 equiv) in 2.0 mL AcOH was cooled to 0 °C, and then NaBH₄ (0.4 mmol, 2.0 equiv) was added successively. The reaction mixture was stirred at 0 °C for 0.5 h until the complete consumption of **3a** as monitored by thin layer chromatography. Then, saturated aq. NH₄Cl solution was added. The mixture was extracted with EA. The combined organic phase was dried over MgSO₄, filtered, concentrated and purified with silica gel column chromatography to obtain **10a** as a white solid (51.8 mg, 77% yield, d.r. = 1:1).



2-(4-(4-Acetylphenyl)pentyl)-2,3-dihydroquinazolin-4(1H)-one (**10a**): White solid (51.8 mg, 77% yield); m.p.: 177.2-179.4 °C; $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.89-7.86 (m, 3H), 7.57 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.25-7.19 (m, 1H), 6.71-6.62 (m, 2H), 6.53 (s, 1H), 4.70-4.61 (m, 1H), 2.79-2.74 (m, 1H), 2.54 (s, 3H), 1.65-1.54 (m, 4H), 1.43-1.26 (m, 2H), 1.20 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 197.9, 164.4, 153.51, 153.47, 149.0, 148.9, 135.3, 133.5, 128.9, 127.8, 127.7, 117.4, 115.5, 114.8, 64.81, 64.79, 37.89, 37.87, 35.5, 35.4, 27.1, 22.4, 22.3, 21.9, 21.8 ppm; HRMS (ESI) calcd for C₂₁H₂₅N₂O₂ [M+H]⁺ 337.1910, found 337.1915.

6. Two-step Telescoping Procedure for the Formation of 3a



A 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was charged with 2aminobenzamide (0.5 mmol, 1.0 equiv), and 2-Methylcyclopentanone (0.55 mmol, 1.1 equiv). Then a solution of Cp₂TiCl₂ (1 mol%) in 2 mL EtOH was added. The reaction mixture was stirred at 50 °C until the reaction was completed as indicated by TLC. The solvent was removed under reduced pressure. Then 4CzIPN (1 mol%), NiCl₂•DME (10 mol%), L2 (12 mol%) and K₂CO₃ (0.2 mmol, 1.0 equiv) were added. Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of 4'-bromoacetophenone 2a (0.2 mmol, 1.0 equiv) in DMSO (2 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. The reaction mixture was quenched with brine (10 mL) and extracted with EtOAc (3×5 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by flash column chromatography (PE/EtOAc=3/1) on silica gel to afford compound 3a (47.5 mg, 71% yield).

7. Investigation of the Reaction Mechanism

7.1 Active Ni(II)-Complex Species Experiment

(a) Preparation of Ni(II) complex C1⁶



In a nitrogen filled glove box, a 50 mL round bottom flask containing a stirring bar was charged with Ni(COD)₂ (138 mg, 0.5 mmol, 1.0 equiv), 4,4'-di-tert-butyl-2,2'-bipyridine (134 mg, 0.5 mmol, 1.0 equiv) and dry THF (5 mL) giving a dark purple mixture which was stirred for 12 h at 25 °C. 1-bromo-4-(trifluoromethyl)benzene (1.4 mL, 10 mmol, 10.0 equiv) was added and stirred for additional 4 h. Dry pentane (30 mL) was added to the deep red colored mixture and filtered. The resulting precipitate was washed with pentane (3×10 mL) and dried under vacum to afford Ni(II) complex C1 as a brown solid (387 mg, 70% yield). The product was used without further purification.

(b) Stoichiometric reactions of Ni(II) complex C1



To a 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was added 4CzIPN (1 mol%), C1 (0.2 mmol, 1.0 equiv) and K₂CO₃ (0.2 mmol, 1.0 equiv). Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of 1a (0.3 mmol, 1.5 equiv), in DMSO (2 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. The reaction mixture was quenched with brine (10 mL) and extracted with EtOAc (3×5 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by flash column chromatography (PE/EA =3/1) on silica gel to afford compound **3f** as a white solid (30.3 mg, 42% yield).



To a 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was added 4CzIPN (1 mol%), C1 (0.04 mmol, 20 mol%) and K_2CO_3 (0.2 mmol, 1.0 equiv). Then, the tube was evacuated and

backfilled with nitrogen for three times. Subsequently, a solution of **1a** (0.3 mmol, 1.5 equiv) and **2a** (0.2 mmol, 1.0 equiv) in DMSO (2 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. The reaction mixture was quenched with brine (10 mL) and extracted with EtOAc (3×5 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by flash column chromatography (PE/EA = 3/1) on silica gel to afford compound **3a** and **3f** as a white solid.

7.2 Radical Trapping and Inhibition Experiments



To a 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was added 4CzIPN (1 mol%), NiCl₂•DME (10 mol%), L2 (12 mol%), K₂CO₃ (0.2 mmol, 1.0 equiv) and TEMPO (0.2 mmol, 1.0 equiv). Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of 1a (0.3 mmol, 1.5 equiv), and 2a (0.2 mmol, 1.0 equiv) in DMSO (2 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. After that, it was found that the formation of 3a was totally inhibited. The crude product was purified by flash column chromatography (PE/EA = 4/1) on silica gel to afford compound 11a as a white solid (68.4 mg, 92% yield).



2-(4-((2,2,6,6-Tetramethylpiperidin-1-yl)oxy)pentyl)quinazolin-4(3H)-one (11a): White solid (70.0 mg, 86% yield); $R_f = 0.2$ (PE/EtOAc = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.06 (brs, 1H), 8.29 (d, J = 8.0 Hz, 1H), 7.79-7.75 (m, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.48-7.44 (m, 1H), 3.99-3.91 (m, 1H), 2.83 (t, J = 6.8 Hz, 2H), 2.03-1.91 (m, 2H), 1.87-1.79 (m, 1H), 1.61-1.37 (m, 6H), 1.33-1.25 (m, 1H), 1.19 (d, J = 6.4 Hz, 3H), 1.09 (s, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 156.8, 149.5, 134.7, 127.2, 126.26, 126.25, 120.5, 77.9, 40.2, 36.2, 35.8, 34.4, 23.9, 20.4, 19.7, 17.3 ppm; HRMS (ESI) calcd for C₂₂H₃₄N₃O₂ [M+H]⁺ 372.2645, found 372.2649.



To a 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was added 4CzIPN (1 mol%), NiCl₂•DME (10 mol%), L2 (12 mol%), K₂CO₃ (0.2 mmol, 1.0 equiv) and BHT (0.2 mmol, 1.0 equiv). Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of 1a (0.3 mmol, 1.5 equiv), and 2a (0.2 mmol, 1.0 equiv) in DMSO (2 mL) was added by

syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. After that, it was found that the formation of **3a** was totally inhibited.

7.3 Radical Clock Experiments⁷



To a 10 mL oven-dried Schlenk-tube equipped with a magnetic stirrer was added 4CzIPN (1 mol%), NiCl₂•DME (10 mol%), L2 (12 mol%), K₂CO₃ (0.2 mmol, 1.0 equiv). Then, the tube was evacuated and backfilled with nitrogen for three times. Subsequently, a solution of 1a (0.3 mmol, 1.5 equiv), 2a (0.2 mmol, 1.0 equiv) and α -cyclopropylstyrene (0.3 mmol, 1.5 equiv) in DMSO (2 mL) was added by syringe under nitrogen atmosphere. The reaction mixture was then irradiated with 10 W blue LEDs at room temperature for 12 h. The reaction mixture was quenched with brine (10 mL) and extracted with EtOAc (3×5 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure yielding crude material, which was purified by silica gel chromatography (PE/EA=3/1), affording 12a as a white solid (19.1 mg, 20%).



2-(9-(4-Acetylphenyl)-4-methyl-6-phenylnon-6-en-1-yl)quinazolin-4(3H)-one (12a): Colorless oil (19.1 mg, 20% yield, Z/E = 2.6:1), $R_f = 0.2$ (PE/EtOAc = 3/1); ¹H NMR (400 MHz, CDCl₃) δ 12.16 (brs, 1H), 8.25 (d, J = 7.2 Hz, 1H), 7.85-7.79(m, 2H), 7.75-7.71 (m, 1H), 7.66-7.63 (m, 1H), 7.43-7.38 (m, 1H), 7.24-7.19 (m, 5H), 7.17-7.11 (m, 2H), 5.62 (t, J = 7.2 Hz, 0.7H), 5.37 (t, J = 7.2 Hz, 0.3H), 2.75 (t, J = 7.6 Hz, 2H), 2.67-2.04 (m, 2H), 2.55 (s, 2H), 2.54 (s, 1H), 2.51-2.43 (m, 2H), 2.33-2.19 (m, 1H), 1.89-1.67 (m, 3H), 1.48-1.38 (m, 2H), 1.23-1.17 (m, 1H), 0.81 (d, J = 6.4 Hz, 1H), 0.76 (d, J = 6.0 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 197.9, 164.0, 156.6, 149.4, 147.7, 143.2, 140.3, 135.1, 134.7, 128.7, 128.6, 128.5, 128.4, 128.2, 128.0, 127.2, 126.7, 126.4, 126.3, 126.2, 120.5, 47.1, 36.9, 36.3, 36.1, 31.4, 30.3, 26.6, 25.0, 19.3.ppm; HRMS (ESI) calcd for C₃₂H₃₅N₂O₂ [M+H]⁺ 479.2693, found 479.2695.

7.4 Steady-State Stern-Volmer Quenching Experiments

Stern-Volmer quenching experiments were carried by PerkinElmer LS-55 spectrofluorophotometer, using a 5×10^{-4} M solution of 4CzIPN with variable concentrations (0.2, 0.4, 0.6, 0.8, 1.0 mM) of **1a**, and **1b** in DMSO (**Figure S2-S4**). The samples were prepared in 20 mL quartz cuvettes. The intensity of the emission peak at 534 nm (λ ex = 365 nm) expressed as the ratio I₀/I, where I₀ is the emission intensity of photocatalyst at 534 nm in the absence of a quencher and I is the observed intensity, as a function of the quencher concentration was measured. Stern-Volmer plots for each component are given below. Stern-Volmer fluorescence quenching experiments revealed that only dihydroquinazolinones **1a** could quench the excited state of 4CzIPN*. These results support the proposed reductive quenching pathway.



Figure S2. a) The fluorescence emission spectra of *4CzIPN with different concentration of **1a** added. (b) The fluorescence emission spectra of *4CzIPN with different concentration of **1a** added.



Figure S3. Stern–Volmer emission quenching studies of 1a and 2a. I₀ is the inherent fluorescence intensity of 4CzIPN. I is the fluorescence intensity of 4CzIPN in the presence of 1a and 2a.

7.5 Light on-off Experiments



Five parallel reactions were performed between **1a** (0.3 mmol, 1.5 equiv), **2a** (0.2 mmol, 1.0 equiv) and according to the General Procedure (**Figure S5**). The resulting residue was purified by silica gel column chromatography (PE/EA = 3/1) to afford the desired products **3a**. The white area indicates the light irradiation, while the grey area indicates time in the dark. The results of light on-off experiments indicated that the reaction proceeded only under the irradiation of light, and the reaction maybe proceed by a catalytic process rather than by a radical chain process.

S21



Figure S5. Light on-off Experiments of 1a and 2a

7.6 Cyclic Voltammetry Analysis

Cyclic voltammetry was conducted on an Electrochemical Workstation using a 3-electrode cell configuration. A glassy carbon working electrode was employed alongside a platinum wire counter electrode and a Ag/AgCl reference electrode. DMSO was degassed by bubbling N₂ prior to measurements. 0.01 M solutions of **1a** in DMSO were freshly prepared along with 0.1 M of TBABF₄ as supporting electrolyte and were examined at a scan 100 mV/s. The results of cyclic voltammetry experiments indicated that the oxidation potential of dihydroquinazolinone **1a** ($E_{1/2}^{ox} = +1.14$ V vs SCE in DMSO) was measured using cyclic voltammetry and was shown to be within the oxidizing power of 4-CzIPN (+1.43 V vs SCE).



Figure S6. Cyclic voltammogram of **1a** in DMSO. Conditions: TBABF₄ (0.1 M), **1a** (10 mM). Scan rate: 100 mV/s.

8. Characterization of Starting Materials Dihydroquinazolinones 1



2-Methyl-1'H-spiro[cyclopentane-1,2'-quinazolin]-4'(3'*H***)-one (1a): White solid; ¹H NMR (400 MHz, DMSO-d_6) \delta 7.91 (s, 1H), 7.54 (d, J =7.6 Hz, 1H), 7.20-7.16 (m 1H), 6.76-6.51 (m, 3H), 2.01-1.88 (m, 2H), 1.81-1.39 (m, 5H), 0.89-0.85 (m, 3H); ¹³C NMR (100 MHz, DMSO-d_6) \delta 163.74, 163.69, 148.0, 147.7, 133.2, 127.2, 127.1, 116.2, 116.0, 114.02, 113.98, 113.8, 78.5, 78.2, 44.4, 44.2, 39.5, 29.4, 29.2, 19.0, 14.4, 13.8 ppm; HRMS** (ESI) calcd for C₁₃H₁₇N₂O [M+H]⁺ 217.1335, found 217.1348.



2-Benzyl-1'*H***-spiro[cyclopentane-1,2'-quinazolin]-4'(3'***H***)-one (1b): White solid; ¹H NMR (400 MHz, CDCl₃) δ 7.91-7.88 (m, 1H), 7.32-7.03 (m, 8H), 6.84-6.78 (m, 1H), 6.68-6.61 (m, 1H), 3.09-3.05 (m, 1H), 2.51-2.38 (m, 1H), 2.32-2.06 (m, 2H), 1.93-1.43 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 165.2, 146.9, 146.2, 140.6, 134.0, 133.9, 128.8, 128.7, 128.33, 128.28, 125.9, 118.6, 118.4, 114.5, 114.0, 79.1, 78.6, 52.2, 51.6, 40.8, 39.8, 35.7, 27.3, 27.2 18.8, 18.6 ppm; HRMS** (ESI) calcd for C₁₉H₂₁N₂O [M+H]⁺ 293.1648, found 293.1657.



2-Heptyl-1'*H*-spiro[cyclopentane-1,2'-quinazolin]-4'(3'*H*)-one (1c): White solid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.83 (s, 1H), 7.50-7.48 (m, 1H), 7.16-7.12 (m, 1H), 6.60-6.51 (m, 3H), 1.96-1.89 (m, 1H), 1.73-1.60 (m, 4H), 1.53-1.36 (m, 3H), 1.27-1.11 (m, 11H), 0.81-1.77 (m, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.4, 148.5, 133.6, 127.6, 116.5, 114.2, 79.0, 50.1, 31.8, 29.8, 29.6, 29.1, 28.3, 27.7, 22.6, 19.5, 14.5 ppm; **HRMS** (ESI) calcd for C₁₉H₂₉N₂O [M+H]⁺ 301.2274, found 301.2282.



2-Cyclopentyl-1'*H*-**spiro[cyclopentane-1,2'-quinazolin]-4'(3'***H***)-one (1d):** White solid; ¹**H NMR** (400 MHz, DMSO-*d*₆) δ 7.87 (s, 1H), 7.53 (d, *J* =7.6 Hz, 1H), 7.19-7.15 (m, 1H), 6.74 (d, *J* =8.0 Hz, 1H), 6.61-6.51 (m, 1H), 6.47 (s, 1H), 1.99-1.94 (m, 1H), 1.88-1.51 (m, 11H), 1.41-1.32 (m, 2H), 1.26-1.17 (m, 1H), 1.09-1.04 (m, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.3, 147.4, 133.1, 127.1, 115.9, 114.1, 113.6, 78.2, 53.3, 41.4, 31.8, 31.2, 27.2, 24.9, 24.1, 19.0 ppm; HRMS (ESI) calcd for C₁₇H₂₃N₂O [M+H]⁺ 271.1805 found 271.1800



2-Methyl-4,5-dihydro-1'*H*,2*H*-spiro[furan-3,2'-quinazolin]-4'(3'*H*)-one (1e): Yellow solid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.16 (s, 1H), 7.59-7.55 (m, 1H), 7.24-7.19 (m, 1H), 6.94 (s, 1H), 6.79-6.67 (m, 1H), 6.64-6.58 (m, 1H), 3.94-3.86 (m, 1H), 3.78-3.71 (m, 1H), 3.63-3.56 (m, 1H), 2.24-2.10 (m, 2H), 1.03-1.01 (m, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.4, 163.3, 147.5, 147.2, 133.6, 133.5, 127.23, 127.17, 116.8, 116.5, 114.0, 113.9, 113.6, 81.6, 81.5, 76.8, 76.5, 63.8, 63.6, 40.4, 39.5, 15.6, 14.3 ppm; **HRMS** (ESI) calcd for C₁₂H₁₅N₂O₂ [M+H]⁺ 219.1128, found 219.1133.



(*IR*,*2R*,*4S*)-1'*H*-spiro[bicyclo[2.2.1]heptane-2,2'-quinazolin]-4'(3'*H*)-one (1f): White solid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.17 (s, 1H), 7.54 (d, *J*=7.2 Hz, 1H), 7.20-7.17 (m, 1H), 6.84 (s, 1H), 6.74 (d, *J*=7.6 Hz, 1H), 6.61-6.58 (m, 1H), 2.27 (s, 1H), 2.01 (s, 1H), 1.85-1.70 (m, 2H), 1.47-1.08 (m, 6H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 163.8, 148.0, 133.6, 127.8, 117.0, 115.9, 114.6, 75.6, 46.5, 45.8, 36.0, 35.7, 28.2, 22.6 ppm; HRMS (ESI) calcd for C₁₄H₁₇N₂O [M+H]⁺ 229.1335, found 229.1342.



(2S,3a'S,4'R,7'R,7a'S)-1',2',3',3a',4',6',7',7a'-Octahydro-1H-spiro[quinazoline-2,5'-

[4,7]methanoinden]-4(3*H*)-one (1g): White solid; ¹H NMR (400 MHz, DMSO- d_6) δ 8.19 (s, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.21-7.17 (m, 1H), 6.80 (s, 1H), 6.73 (d, J = 7.6 Hz, 1H), 6.60 (t, J = 7.6 Hz, 1H), 2.14-2.07 (m, 1H), 2.04 (s, 1H), 1.92-1.76 (m, 4H), 1.65-1.53 (m, 2H), 1.48 (d, J = 10.8 Hz, 1H), 1.23 (d, J = 10.0 Hz, 2H), 1.14-1.02 (m, 1H), 0.90-0.75 (m, 2H); ¹³C NMR (100 MHz, DMSO- d_6) δ 163.9, 147.9, 133.6, 127.8, 117.0, 115.8, 114.7, 75.1, 51.1, 46.7, 45.2, 40.2, 40.1, 32.4, 31.5, 30.0, 27.7 ppm; HRMS (ESI) calcd for C₁₇H₂₁N₂O [M+H]⁺ 269.1648 found 269.1640.



Methyl2-(4-((4'-oxo-3',4'-dihydro-1'H-spiro[cyclopentane-1,2'-quinazolin]-2-yl)methyl)phenyl)propanoate (1h): White solid; ¹H NMR (400 MHz, DMSO- d_6) δ 8.07-8.02 (m, 1H),7.59-7.53 (m, 1H), 7.19-7.02 (m, 5H), 6.77-6.55 (m, 3H), 3.71-3.66 (m, 1H), 3.52 (s, 3H), 2.84-2.78 (m,1H), 2.39-2.32 (m, 1H), 2.15-1.99 (m, 2H), 1.76-1.64 (m, 2H), 1.56-1.44 (m, 3H), 1.31 (d, J = 6.8 Hz,3H); ¹³C NMR (100 MHz, DMSO- d_6) δ 174.5, 163.8, 163.6, 161.9, 157.0, 149.0, 148.1, 147.5, 140.0,138.0, 134.3, 133.3, 128.83, 128.78, 127.32, 127.27, 127.2, 126.9, 126.0, 125.7, 121.0, 116.3, 114.3,114.0, 113.9, 78.5, 78.1, 51.8, 51.1, 50.5, 44.1, 39.9, 34.9, 33.7, 26.7, 26.6, 18.8, 18.71, 18.66, 18.6 ppm;HRMS (ESI) calcd for C₂₃H₂₆N₂O₃ [M+H]⁺ 379.2016, found 379.2017



2,3'-Dimethyl-1'H-spiro[cyclopentane-1,2'-quinazolin]-4'(3'H)-one (1i): White solid; ¹H NMR (400

MHz, DMSO- d_6) δ 7.55-7.52 (m, 1H), 7.18-7.15 (m, 1H), 6.78-6.75 (m, 1H), 6.58-6.55 (m, 1H), 6.42 (s, 1H), 3.07-2.82 (m, 3H), 2.35-2.20 (m, 1H), 1.99-1.56 (m, 6H), 0.88-0.85 (m, 3H); ¹³C NMR (100 MHz, DMSO- d_6) δ 163.7, 147.1, 133.5, 127.9, 116.9, 114.7, 114.5, 82.3, 40.9, 35.2, 29.7, 27.2, 20.0, 13.7 ppm; **HRMS** (ESI) calcd for C₁₄H₁₉N₂O [M+H]⁺ 231.1492, found 231.1500.

6'-Fluoro-2-methyl-1'H-spiro[cyclopentane-1,2'-quinazolin]-4'(3'H)-one (1j): White solid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.01 (s, 1H), 7.30-7.19 (m, 1H), 7.14-7.03 (m, 1H), 6.79-6.51 (m, 2H), 2.07-1.86 (m, 2H), 1.77-1.43 (m, 5H), 0.88 (s, 1.4H), 0.86 (s, 1.6H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 162.9, 155.3 (d, *J*_{C-F} = 230.7 Hz), 144.8, 120.8, 120.5, 115.5, 115.4, 114.8, 114.7, 112.5, 112.2, 78.7, 44.2, 39.3, 29.4, 19.0, 14.5 ppm; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -127.90 ppm; HRMS (ESI) calcd for C₁₃H₁₆FN₂O [M+H]⁺ 235.1241, found 235.1247.



2,6'-Dimethyl-1'*H***-spiro[cyclopentane-1,2'-quinazolin]-4'(3'***H***)-one (1k): White solid; ¹H NMR (400 MHz, DMSO-***d***₆) δ 7.87-7.85 (m, 1H), 7.36 (s, 1H), 7.01 (d,** *J* **= 8.0 Hz, 1H), 6.69-6.56 (m, 1H), 6.40 (s, 0.5H), 6.32 (s, 0.5H), 2.15 (s, 3H), 1.99-1.86 (m, 2H), 1.76-1.52 (m, 4H), 1.46-1.38 (m, 1H), 0.89-0.84 (m, 3H); ¹³C NMR (100 MHz, DMSO-***d***₆) δ 163.9, 163.8, 145.9, 145.6, 134.02, 133.98, 127.1, 127.0, 124.7, 124.5, 114.13, 114.06, 114.0, 78.5, 78.2, 44.2, 44.0, 39.3 29.5, 29.2, 20.2, 19.04, 19.00, 14.5, 13.9 ppm; HRMS** (ESI) calcd for C₁₄H₁₉N₂O [M+H]⁺ 231.1492, found 231.1504.

7'-Chloro-2-methyl-1'H-spiro[cyclopentane-1,2'-quinazolin]-4'(3'*H***)-one (11): White solid; ¹H NMR (400 MHz, DMSO-***d***₆) δ 8.00 (s, 1H), 7.51-7.48 (m, 1H), 6.89-6.54 (m, 3H), 1.95-1.40 (m, 7H), 0.85-0.81 (m, 3H); ¹³C NMR (100 MHz, DMSO-***d***₆) δ 163.2, 149.4, 149.1, 138.1, 129.6, 129.5, 116.5, 116.4, 113.4, 113.2, 79.1, 45.2, 44.9, 29.8, 29.5, 19.43, 19.37, 14.7, 14.1 ppm; HRMS (ESI) calcd for C₁₃H₁₆ClN₂O [M+H]⁺ 251.0946, found 251.0952.**



4,5-Dihydro-1'*H***,2***H***-spiro[furan-3,2'-quinazolin]-4'(3'***H***)-one (1m): Pale yellow solid; ¹H NMR (400 MHz, DMSO-d_{\delta}) \delta 8.31 (s, 1H), 7.27 (d, J =8.0 Hz, 1H), 7.23-7.19 (m, 1H), 7.06 (s, 1H), 6.71 (d, J = 8.0 Hz, 1H), 6.64 (t, J = 7.2 Hz, 1H), 3.90-3.79 (m, 2H), 3.64 (d, J = 8.8 Hz, 1H), 3.54 (d, J = 9.2 Hz, 1H), 2.16-2.01 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) \delta 163.9, 147.6, 133.9, 127.9, 117.7, 115.0, 114.8, 77.2, 76.4, 66.6, 39.8 ppm; HRMS (ESI) calcd for C₁₁H₁₃N₂O₂ [M+H]⁺ 205.0972, found 205.0986.**



Benzyl 4'-oxo-3',4'-dihydro-1'*H***-spiro[pyrrolidine-3,2'-quinazoline]-1-carboxylate (1n):** White solid; ¹**H NMR** (400 MHz, DMSO- d_6) δ 8.41 (s, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.35-7.22 (m, 6H), 7.11 (s, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.67 (t, J = 7.6 Hz, 1H), 5.09-5.03 (m, 2H), 3.53-3.36 (m, 4H), 2.12-2.02 (m, 2H); ¹³**C NMR** (100 MHz, CDCl₃) δ 163.9, 154.5, 147.3, 137.5, 134.0, 128.9, 128.3, 128.1, 128.0, 127.9, 118.0, 115.2, 114.9, 74.9, 74.1, 66.4, 57.1, 56.8, 43.9, 43.6, 40.0, 37.8, 37.0 ppm; **HRMS** (ESI) calcd for C₁₉H₂₀N₃O₃ [M+H]⁺ 338.1499, found 338.1490.



5,6-Dihydro-1'*H***,2***H***,4***H***-spiro[pyran-3,2'-quinazolin]-4'(3'***H***)-one (10):** White solid; ¹**H NMR** (400 MHz, DMSO- d_6) δ 7.92 (s, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.22-7.17 (m, 1H), 6.81-6.79 (m, 2H), 6.62-6.58 (m, 1H), 3.66-3.62 (m, 1H), 3.55 (d, J = 10.8 Hz, 1H), 3.36-3.29 (m, 1H), 3.24 (d, J =10.8 Hz, 1H), 1.88-1.60 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 163.6, 147.1, 133.9, 127.7, 117.3, 115.2, 114.6, 73.7, 67.5, 65.7, 35.0, 21.8 ppm; HRMS (ESI) calcd for C₁₂H₁₅N₂O₂ [M+H]⁺ 219.1128, found 219.1135.



1'H-Spiro[cyclopentane-1,2'-quinazolin]-4'(3'H)-one (1p): White solid; ¹H NMR (400 MHz, DMSO d_6) δ 8.08 (s, 1H), 7.57 (d, *J* =8.0 Hz, 1H), 7.24-7.19 (m, 1H), 6.74-6.69 (m, 2H), 6.63 (t, *J* =7.2 Hz, 1H), 1.80-1.65 (m, 8H); ¹³C NMR (100 MHz, DMSO- d_6) δ 163.9, 148.0, 133.5, 127.7, 117.0, 115.0, 114.8, 77.5, 39.8, 22.5 ppm; HRMS (ESI) calcd for C₁₂H₁₅N₂O [M+H]⁺ 203.1179, found 203.1188.



1'H-Spiro[cyclohexane-1,2'-quinazolin]-4'(3'H)-one (1q): White solid; ¹H NMR (400 MHz, CDCl₃) δ 7,91 (s, 1H), 7.57 (d, J =7.6 Hz, 1H), 7.24-7.20 (m, 1H), 6.81 (d, J =8.0 Hz, 1H), 6.64-6.61 (m, 2H), 1.77-1.74 (m, 2H), 1.64-1.55 (m, 6H), 1.44-1.41 (m, 1H), 1.30-1.22 (1H); ¹³C NMR (100 MHz, CDCl₃) δ 163.6, 147.2, 133.6, 127.5, 116.9, 115.0, 114.9, 68.3, 37.6, 25.1, 21.3 ppm; HRMS (ESI) calcd for C₁₃H₁₇N₂O [M+H]⁺ 217.1335, found 217.1348.

9. Characterization of Products



2-(4-(4-Acetylphenyl)pentyl)quinazolin-4(3H)-one (3a): White solid (60.2 mg, 90% yield), m.p.: 172.2-173.4 °C; $R_f = 0.2$ (PE/EA = 3/1); ¹H NMR (400 MHz, CDCl₃) δ 12.25 (brs, 1H), 8.24 (d, J = 7.2 Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.77 (t, J = 8.4 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 2.87-2.77 (m, 3H), 2.51(s, 3H), 1.90-1.75 (m, 4H), 1.27 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 164.4, 156.6, 152.9, 149.3, 135.1, 134.8, 128.6, 127.1, 126.4, 126.1, 120.3, 39.8, 37.3, 35.6, 26.5, 25.5, 22.0 ppm; HRMS (ESI) calcd for C₂₁H₂₃N₂O₂ [M+H]⁺ 335.1754, found 335.1763.



2-(4-(Methylsulfonyl)phenyl)pentyl)quinazolin-4(3*H***)-one (3b): White solid (60.0 mg, 81% yield), m.p.: 180.6-182.1 °C; R_f = 0.2 (PE/EtOAc = 1:1); ¹H NMR (400 MHz, CDCl₃) \delta 12.16 (brs, 1H), 8.25 (d, J = 7.2 Hz, 1H), 7.81 (d, J = 8.4 Hz, 2H), 7.78 (t, J = 8.4 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 3.01 (s, 3H), 2.90-2.83 (m, 1H), 2.78 (t, J = 6.4 Hz, 2H), 1.88-1.73 (m, 4H), 1.28 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 164.4, 156.4, 153.7, 149.3, 138.1, 134.9, 128.0, 127.5, 127.2, 126.4, 126.0, 120.4, 44.5, 39.8, 37.3, 35.5, 25.3, 21.9 ppm; HRMS (ESI) calcd for C₂₀H₂₃N₂O₃S [M+H]⁺ 371.1424, found 371.1430.**



Ethyl 4-(5-(4-oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)benzoate (3c): White solid (56.1 mg, 77% yield), m.p.: 165.7-167.1 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.16 (brs, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.91 (d, J = 8.0 Hz, 2H), 7.77 (t, J = 8.4 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.24 (d, J = 8.0 Hz, 2H), 4.33 (q, J = 6.8 Hz, 2H), 2.87-2.81 (m, 1H), 2.78 (t, J = 7.2 Hz, 2H), 1.90-1.75 (m, 4H), 1.35 (t, J = 7.2 Hz, 3H), 1.27 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.5, 164.4, 156.6, 152.5, 149.3, 134.8, 129.7, 128.3, 127.1, 126.9, 126.4, 126.1, 120.3, 60.7, 39.8, 37.4, 35.6, 25.5, 22.0, 14.3 ppm; HRMS (ESI) calcd for C₂₂H₂₅N₂O₃ [M+H]⁺ 365.1860, found 365.1865.



4-(5-(4-Oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)benzaldehyde (3d): White solid (50.6 mg, 79% yield), m.p.: 177.9-179.0 °C; $R_f = 0.2$ (PE/EtOAc = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.28 (brs, 1H), 9.89 (s, 1H), 8.23 (d, J = 7.6 Hz, 1H), 7.78 (t, J = 8.4 Hz, 1H), 7.73 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H), 2.91-2.82 (m, 1H), 2.79 (t, J = 6.4 Hz, 2H), 1.91-1.75 (m, 4H), 1.28 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ

191.9, 164.5, 156.5, 154.5, 149.4, 134.8, 134.6, 130.0, 127.6, 127.2, 126.4, 126.0, 120.3, 40.0, 37.3, 35.6, 25.4, 21.9 ppm; **HRMS** (ESI) calcd for C₂₀H₂₁N₂O₂ [M+H]⁺ 321.1598, found 321.1604.



4-(5-(4-Oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)benzonitrile (3e): White solid (52.0 mg, 82% yield), m.p.: 185.0-187.2 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹**H NMR** (400 MHz, CDCl₃) δ 12.05 (brs, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.79 (t, J = 8.4 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.53-7.47 (m, 3H), 7.28 (d, J = 8.4 Hz, 2H), 2.88-2.82 (m, 1H), 2.78 (t, J = 6.4 Hz, 2H), 1.91-1.72 (m, 4H), 1.27 (d, J = 7.2 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃) δ 164.3, 156.5, 152.7, 149.0, 135.0, 132.3, 127.8, 127.1, 126.5, 126.1, 120.3, 119.0, 109.8, 39.9, 37.2, 35.4, 25.3, 21.9 ppm; **HRMS** (ESI) calcd for C₂₀H₂₀N₃O [M+H]⁺ 318.1601, found 318.1603.



2-(4-(4-(Trifluoromethyl)phenyl)pentyl)quinazolin-4(3*H***)-one (3f): White solid (47.6 mg, 66% yield), m.p.: 169.9-171.8 °C; R_f = 0.2 (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) \delta 12.15 (brs, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.80-7.76 (m, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.49-7.46 (m, 3H), 7.29 (d, J = 8.0 Hz, 2H), 2.89-2.78 (m, 3H), 1.92-1.73 (m, 4H), 1.27 (d, J = 6.8 Hz, 3H); ¹⁹F NMR (376 MHz, CDCl₃) \delta -62.17 (s, 3F); ¹³C NMR (100 MHz, CDCl₃) \delta 164.6, 156.6, 151.2, 149.5, 134.8, 128.2 (q, J_{C-F} = 32.2 Hz), 127.2 (2C), 126.3, 126.0, 125.3 (q, J_{C-F} = 3.7 Hz), 124.2 (q, J_{C-F} = 270.3 Hz), 120.3, 39.6, 37.4, 35.6, 25.4, 22.0 ppm; HRMS (ESI) calcd for C₂₀H₂₀F₃N₂O [M+H]⁺ 361.1522 found 361.1525.**



2-(4-(4-Benzoylphenyl)pentyl)quinazolin-4(3*H***)-one (3g): White solid (45.2 mg, 57% yield), m.p.: 190.9-192.0 °C; R_f = 0.2 (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) \delta 12.32 (brs, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.77-7.67 (m, 6H), 7.56 (t, J = 8.0 Hz, 1H), 7.47-7.43 (m, 3H), 7.29 (d, J = 8.0 Hz, 2H), 2.89-2.84 (m, 1H), 2.80 (t, J = 6.4 Hz, 2H), 1.97-1.78 (m, 4H), 1.29 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 196.3, 164.5, 156.6, 152.3, 149.3, 137.7, 135.3, 134.8, 132.1, 130.4, 129.8, 128.1, 127.1, 126.9, 126.3, 126.0, 120.3, 39.8, 37.4, 35.6, 25.5, 22.0 ppm; HRMS (ESI) calcd for C₂₆H₂₅N₂O₂ [M+H]⁺ 397.1911, found 397.1915.**



2-(4-(4-Chlorophenyl)pentyl)quinazolin-4(3*H***)-one (3h):** White solid (41.2 mg, 63% yield), m.p.: 184.4-186.0 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.27 (brs, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.80, 7.80-7.76 (m, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.50-7.46 (m, 1H), 7.18 (d, J = 8.4

Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 2.83-2.72 (m, 3H), 1.91-1.69 (m, 4H), 1.23 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 156.6, 149.4, 145.5, 134.8, 131.5, 128.4, 128.3, 127.2, 126.3, 126.1, 120.4, 39.1, 37.6, 35.7, 25.5, 22.3 ppm; HRMS (ESI) calcd for C₁₉H₂₀ClN₂O [M+H]⁺ 327.1259, found 327.1262.



2-(4-([1,1'-Biphenyl]-4-yl)pentyl)quinazolin-4(3*H***)-one (3i): White solid (28.0 mg, 38% yield), m.p.: 187.6-189.2 °C; R_f = 0.2 (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) \delta 12.26 (brs, 1H), 8.30 (d, J = 8.0 Hz, 1H), 7.79-7.75 (m, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.54-7.52 (m, 2H), 7.49-7.45 (m, 3H), 7.43-7.39 (m, 2H), 7.34-7.30 (m, 1H), 7.26 (d, J = 8.4 Hz, 2H), 2.87-2.79 (m, 3H), 1.94-1.76 (m, 4H), 1.31 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 164.5, 156.8, 149.5, 146.2, 140.9, 138.8, 134.7, 128.6, 127.3, 127.2, 127.0, 126.9, 126.3, 126.1, 120.4, 39.3, 37.7, 35.8, 25.7, 22.3 ppm; HRMS (ESI) calcd for C₂₅H₂₅N₂O [M+H]⁺ 369.1961, found 369.1964.**



2-(4-(4-(Trifluoromethoxy)phenyl)pentyl)quinazolin-4(3*H***)-one (3j): White solid (14.3 mg, 19% yield), m.p.: 161.7-169.2 °C; R_f = 0.2 (PE/EtOAc = 4/1); ¹H NMR (400 MHz, CDCl₃) \delta 12.15 (brs, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.80-7.76 (m, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.50-7.46 (m, 1H), 7.19 (d, J = 8.8 Hz, 2H), 7.07 (d, J = 8.0 Hz, 2H), 2.81-2.77 (m, 3H), 1.93-1.70 (m, 4H), 1.25 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 164.4, 156.6, 149.3, 147.3, 145.8, 134.9, 128.1, 127.2, 126.4, 126.1, 120.9, 120.44 (q, J_{C-F} = 254.9 Hz), 120.36, 39.1, 37.6, 35.7, 25.5, 22.2 ppm; HRMS (ESI) calcd for C₂₀H₂₀F₃N₂O₂ [M+H]⁺ 377.1471, found 377.1475.**



2-(4-(3-Acetylphenyl)pentyl)quinazolin-4(3*H***)-one (3k):** Colorless oil (46.8 mg, 70% yield), $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 11.90 (brs, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.79-7.75 (m, 2H), 7.72 (dt, J = 7.6 Hz, 1.2 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.49-7.45 (m, 1H), 7.40-7.38 (m, 1H), 7.34-7.30 (m, 1H), 2.89-2.81 (m, 1H), 2.77 (t, J = 6.8 Hz, 2H), 2.56 (s, 3H), 1.91-1.74 (m, 4H), 1.28 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 198.2, 164.4, 156.6, 149.3, 147.6, 137.0, 134.6, 131.7, 128.4, 127.0, 126.5, 126.21, 126.16, 126.0, 120.2, 39.5, 37.4, 35.5, 26.5, 25.4, 22.0 ppm; HRMS (ESI) calcd for C₂₁H₂₃N₂O₂ [M+H]⁺ 335.1754, found 335.1758.



2-(4-(3-Chlorophenyl)pentyl)quinazolin-4(3*H***)-one (3l):** White solid (38.5 mg, 59% yield), m.p.: 185.4-187.1 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.02 (brs, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.80-7.76 (m, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.16-7.09 (m, 3H), 7.05 (d, J = 7.2 Hz, 1H), 2.82-2.71 (m, 3H), 1.92-1.72 (m, 4H), 1.25 (d, J = 6.8 Hz, 3H); ¹³C

NMR (100 MHz, CDCl₃) δ 164.4, 156.5, 149.4, 149.2, 134.8, 134.1, 129.6, 127.2, 127.1, 126.4, 126.2, 126.1, 125.2, 120.4, 39.6, 37.5, 35.7, 25.4, 22.1; **HRMS** (ESI) calcd for C₁₉H₂₀ClN₂O [M+H]⁺ 327.1259, found 327.1260.



2-(4-(3-Oxo-2,3-dihydro-1H-inden-5-yl)pentyl)quinazolin-4(3*H***)-one (3m): White solid (58.9 mg, 85% yield), m.p.:188.0-190.1 °C; R_f = 0.2 (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) \delta 11.85 (brs, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 8.4 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 3.03 (t, J = 5.6 Hz, 2H), 2.91-2.83 (m, 1H), 2.78 (t, J = 6.4 Hz, 2H), 2.62 (t, J = 6.0 Hz, 2H), 1.92-1.76 (m, 4H), 1.28 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) \delta 206.6, 164.3, 156.4, 155.8, 154.9, 149.4, 135.4, 134.9, 127.2, 126.5, 126.4, 126.1, 125.0, 123.8, 120.4, 40.2, 37.4, 36.4, 35.7, 25.7, 25.5, 22.2 ppm; HRMS (ESI) calcd for C₂₂H₂₃N₂O₂ [M+H]⁺ 347.1754, found 347.1755.**



2-(4-(3-Oxo-1,3-dihydroisobenzofuran-5-yl)pentyl)quinazolin-4(3H)-one (3n): White solid (42.5 mg, 61% yield), m.p.:178.1-180.0 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.10 (brs, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.80-7.76 (m, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.49-7.45 (m, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.28 (s, 1H), 5.19 (m, 2H), 2.96-2.76 (m, 3H), 1.92-1.73 (m, 4H), 1.30 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.0, 164.4, 156.3, 154.4, 149.3, 147.2, 134.9, 128.3, 127.2, 126.5, 126.0, 125.7, 123.7, 120.4, 120.3, 69.5, 40.2, 37.4, 35.5, 25.3, 22.2 ppm; HRMS (ESI) calcd for C₂₁H₂₁N₂O₃ [M+H]⁺ 349.1547, found 349.1550.



2-(4-(Quinolin-3-yl)pentyl)quinazolin-4(3H)-one (3o): Colorless oil (41.9 mg, 61% yield), $R_f = 0.2$ (PE/EA = 1:1); ¹H NMR (400 MHz, CDCl₃) δ 12.35 (brs, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.76-7.72 (m, 1H), 7.68-7.65 (m, 2H), 7.61-7.57 (m, 1H), 7.46-7.41 (m, 2H), 3.02-2.96 (m, 1H), 2.80 (d, J = 6.0 Hz, 2H), 1.99-1.81 (m, 4H), 1.36 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 156.4, 151.0, 149.3, 146.8, 139.5, 134.7, 132.8, 128.8, 128.6, 128.1, 127.3, 127.1, 126.5, 126.3, 126.1, 120.3, 37.3, 37.3, 35.5, 25.3, 21.9 ppm; HRMS (ESI) calcd for C₂₂H₂₂N₃O [M+H]⁺ 344.1757, found 344.1760.



2-(4-(Quinolin-6-yl)pentyl)quinazolin-4(3H)-one (3p): Colorless oil (37.7 mg, 55% yield), $R_f = 0.2$ (PE/EA = 1:1); ¹H NMR (400 MHz, CDCl₃) δ 12.30 (brs, 1H), 8.78 (dd, J = 4.4 Hz, 1.6 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 9.2 Hz, 2H), 7.75-7.71 (m, 1H), 7.65 (d, J = 7.6 Hz, 1H),

7.55-7.52 (m, 2H), 7.42 (t, J = 8.0 Hz, 1H), 7.28-7.25 (m, 1H), 2.98-2.90 (m, 1H), 2.78 (t, J = 6.4 Hz, 2H), 1.92-1.76 (m, 4H), 1.31 (d, J = 7.2 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃) δ 164.3, 156.6, 149.4, 149.3, 146.9, 145.4, 135.7, 134.7, 129.2, 129.1, 128.2, 127.1, 126.3, 126.0, 124.9, 120.9, 120.3, 39.6, 37.3, 35.6, 25.5, 22.2 ppm; **HRMS** (ESI) calcd for C₂₂H₂₂N₃O [M+H]⁺ 344.1757, found 344.1759.



2-(4-(Pyridin-4-yl)pentyl)quinazolin-4(3H)-one (3q): Colorless oil (37.6 mg, 64% yield), $R_f = 0.2$ (PE/EA = 1:1); ¹H NMR (400 MHz, CDCl₃) δ 12.53 (brs, 1H), 8.43 (d, J = 6.0 Hz, 2H), 8.23 (d, J = 8.0 Hz, 1H), 7.77-7.73 (m, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.47-7.43 (m, 1H), 7.09 (d, J = 6.0 Hz, 2H), 2.79-2.72 (m, 3H), 1.89-1.70 (m, 4H), 1.23 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 156.5, 156.1, 149.5, 149.3, 134.7, 127.1, 126.3, 126.0, 122.5, 120.4, 39.1, 36.8, 35.5, 25.3, 21.4 ppm; HRMS (ESI) calcd for C₁₈H₂₀N₃O [M+H]⁺ 294.1601, found 294.1602.



2-(4-(Naphthalen-2-yl)pentyl)quinazolin-4(3H)-one (3r): White solid (15.1 mg, 22% yield), m.p.:187.8-190.0 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.22 (brs, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.79-7.69 (m, 5H), 7.60 (m, 1H), 7.48-7.44 (m, 1H), 7.41-7.32 (m, 3H), 2.99-2.90 (m, 1H), 2.80 (t, J = 6.8 Hz, 2H), 1.95-1.79 (m, 4H), 1.35 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 156.7, 149.4, 144.5, 134.7, 133.5, 132.1, 127.9, 127.5, 127.4, 127.2, 126.3, 126.1, 125.8, 125.5, 125.14, 125.05, 120.4, 39.8, 37.5, 35.8, 25.6, 22.3 ppm; HRMS (ESI) calcd for C₂₃H₂₃N₂O [M+H]⁺ 343.1805, found 343.1810.



2-(4-Methyl-6-phenylhex-5-en-1-yl)quinazolin-4(3H)-one (3s): White solid (45.8 mg, 72% yield), m.p.:171.2-172.9 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.22 (brs, 1H), 8.29 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 7.22 (d, J = 7.2 Hz, 2H), 7.15 (t, J = 7.2 Hz, 1H), 6.36 (d, J = 16.0 Hz, 1H), 6.11 (d, J = 8.0 Hz, 0.5H), 6.07 (d, J = 8.0 Hz, 0.4H), 2.82 (t, J = 8.0 Hz, 2H), 2.44-2.34 (m, 1H), 2.00-1.88 (m, 2H), 1.57 (m, 2H), 1.12 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 156.8, 149.5, 137.6, 136.1, 134.7, 128.5, 128.4, 127.2, 126.8, 126.3, 126.2, 125.9, 120.4, 37.1, 36.5, 35.9, 25.4, 20.6 ppm; HRMS (ESI) calcd for C₂₁H₂₃N₂O [M+H]⁺ 319.1805, found 319.1807.



4-(3-Methyl-6-(4-oxo-3,4-dihydroquinazolin-2-yl)hex-1-yn-1-yl)benzonitrile (3t): White solid

(49.8 mg, 73% yield), m.p.:176.3-177.9 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.31 (brs, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.47-7.45 (m, 3H), 7.38 (d, J = 8.0 Hz, 2H), 2.87 (t, J = 8.0 Hz, 2H), 2.82-2.74 (m, 1H), 2.22-2.02 (m, 2H), 1.71 (m, 2H), 1.29 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.5, 156.4, 149.4, 134.8, 132.0, 131.7, 128.8, 127.2, 126.4, 126.1, 120.4, 118.5, 110.7, 99.0, 80.0, 36.0, 35.5, 26.5, 25.3, 20.7 ppm; HRMS (ESI) calcd for C₂₂H₂₀N₃O [M+H]⁺ 342.1601, found 342.1603.



(*1R*,*2R*,*5R*)-2-isopropyl-5-methylcyclohexyl 4-(5-(4-oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)benzoate (3v): Colorless oil (75.9 mg, 80% yield, d.r. = 1:1), $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.00 (brs, 1H), 8.29-8.25 (m, 1H), 7.94 (d, J = 8.4 Hz, 2H), 7.79-7.75 (m, 1H), 7.72-7.67 (m, 1H), 7.49-7.45 (m, 1H), 7.26 (d, J = 8.4 Hz, 2H), 4.90 (td, J = 11.2, 4.0 Hz, 1H), 2.87-2.75 (m, 3H), 1.96-1.70 (m, 8H), 1.58-1.38 (m, 5H), 1.27 (d, J = 6.8 Hz, 3H), 0.94-0.89 (m, 6H), 0.77 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.0, 164.5, 157.1, 156.6, 152.4, 149.4, 134.7, 129.7, 128.6, 127.2, 126.9, 126.3, 126.1, 120.4, 74.5, 47.2, 40.9, 39.7, 37.4, 35.8, 35.6, 34.3, 31.4, 27.2, 26.4, 25.5, 23.5, 22.3, 22.0, 20.7, 16.4, 13.9 ppm; HRMS (ESI) calcd for C₃₀H₃₉N₂O₃ [M+H]⁺ 475.2955, found 475.2956.



(2,2,7,7-Tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl 4-(5-(4-oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)benzoate (3w): Colorless paste (60.2 mg, 52% yield, d.r. = 1:1), $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 12.28 (brs, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.76 (t, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.25 (d, J = 9.2 Hz, 2H), 4.64-4.61 (m, 2H), 4.44-4.43 (m, 1H), 4.30 (d, J = 12.0 Hz, 1H), 4.24 (d, J = 8.0 Hz, 1H), 3.94 (d, J = 12.8 Hz, 1H), 3.78 (d, J = 12.8 Hz, 1H), 2.86-2.76 (m, 3H), 1.91-1.74 (m, 4H), 1.52 (s, 3H), 1.45 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H), 1.26 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 165.8, 164.4, 156.5, 152.8, 149.4, 134.8, 129.9, 127.6, 127.2, 127.0, 126.3, 126.0, 120.4, 109.1, 108.7, 101.6, 70.7, 70.4, 70.0, 65.1, 61.3, 39.7, 37.4, 35.6, 26.5, 25.8, 25.5, 25.4, 24.0, 21.9; HRMS (ESI) calcd for C₃₂H₃₉N₂O₈ [M+H]⁺ 579.2701, found 579.2712.



4-((*R*)-5-(4-Oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)-*N*-((*R*)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-

yl)benzenesulfonamide (3x): Colorless oli (82.2 mg, 54% yield, d.r. = 1.7/1), $R_f = 0.1$ (PE/EA = 1:3); ¹H NMR (400 MHz, CDCl₃) δ 11.91 (brs, 0.6H), 11.86 (brs, 0.4H), 8.24-8.17 (m, 1H), 7.76-7.61 (m, 2H), 7.45-7.37 (m, 3H), 7.28-7.26 (m, 1H), 7.15-7.07 (m, 2H), 6.87-6.79 (m, 1H), 6.61-6.44 (m, 1H), 5.40-4.88 (m, 2H), 4.45-4.08 (m, 3H), 3.98-3.78 (m, 2H), 2.94-2.62 (m, 7H), 1.80-1.68 (m, 4H), 1.26-1.21 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.8, 169.5, 163.92, 163.89, 156.5, 152.4, 150.15, 149.3, 137.5, 134.7, 127.4, 127.1, 126.7, 126.3, 126.0, 120.9 (q, $J_{C-F} = 270.0$ Hz), 120.41, 116.8, 105.3-104.8 (m), 60.3, 52.3, 43.0, 42.9, 39.5, 39.4, 38.8, 38.7, 38.1, 37.3, 35.5, 33.8, 25.4, 25.3, 21.5, 21.4 ppm; HRMS (ESI) calcd for C₃₅H₃₄F₆N₇O₄S [M+H]⁺ 762.2292, found 762.2340.



N-((*R*)-1-(3-(2-Cyanobenzyl)-1-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)piperidin-3-yl)-4-((*R*)-5-(4-oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)benzenesulfonamide (3y): Colorless oil (94.4 mg, 68% yield, d.r. = 1:1), $R_f = 0.1$ (PE/EA = 1/3); ¹H NMR (400 MHz, CDCl₃) δ 11.51 (brs, 1H), 8.18 (d, *J* = 8.0 Hz, 1H), 7.75-7.69 (m, 3H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.56-7.54 (m, 1H), 7.51-7.41 (m, 2H), 7.29-7.26 (m, 4H), 6.24 (s, 1H), 5.28 (s, 1H), 5.19 (s, 2H), 3.41-3.31 (m, 1H), 3.23 (s, 3H), 3.06-2.60 (m, 6H), 1.92-1.60 (m, 6H), 1.55-1.36 (m, 2H), 1.24-1.23 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 163.7, 163.1, 159.4, 156.3, 152.6, 152.2, 149.2, 140.3, 138.1, 134.7, 133.0, 133.0, 127.9, 127.8, 127.4, 127.1, 126.9, 126.4, 126.0, 120.3, 117.2, 110.7, 90.3, 56.2, 52.1, 48.8, 46.2, 39.6, 37.2, 35.5, 29.6, 27.9, 25.38, 25.35, 21.9 ppm; HRMS (ESI) calcd for C₃₇H₄₀N₇O₅S [M+H]⁺ 694.2806, found 694.2800.



N-(((*1S*,*4aR*)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1yl)methyl)-4-((*R*)-5-(4-oxo-3,4-dihydroquinazolin-2-yl)pentan-2-yl)benzenesulfonamide (3): Colorless oil (39.7 mg, 31% yield, , d.r. = 1:1), $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 11.86 (brs, 1H), 8.22 (d, *J* = 8.0 Hz, 1H), 7.75-7.66 (m, 4H), 7.47-7.43 (m, 1H), 7.30-7.26 (m, 3H), 7.11 (d, *J* = 8.0 Hz, 1H), 6.95 (d, *J* = 8.0 Hz, 1H), 6.83 (s, 1H), 5.30 (s, 1H), 2.85-2.64 (m, 7H), 1.93-1.52 (m, 11H), 1.30-1.16 (m, 12H), 1.01-0.91 (m, 2H), 0.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.1, 156.4, 152.3, 149.3, 146.9, 145.5, 137.8, 134.8, 134.6, 128.1, 127.7, 127.1, 126.8, 126.4, 126.1, 124.1, 123.7, 120.5, 53.7, 44.5, 39.7, 38.1, 37.3, 37.0, 35.6, 33.38, 29.8, 29.6, 25.4, 25.2, 24.0, 23.9, 21.9, 18.6, 18.6, 18.5 ppm; HRMS (ESI) calcd for C₃₉H₅₀N₃O₃S [M+H]⁺ 640.3576, found 640.3581.



2-(4-(4-Acetylphenyl)-5-phenylpentyl)quinazolin-4(3H)-one (5a): White solid (63.2 mg, 69% yield), m.p.:186.8-187.9 °C; $R_f = 0.2$ (PE/EA = 4/1). ¹H NMR (400 MHz, CDCl₃) δ 12.28 (brs, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.80-7.76 (m, 3H), 7.69 (d, J = 8.0 Hz, 1H), 7.49-7.45 (m, 1H), 7.18 (d, J = 8.4 Hz, 2H), 7.16-7.09 (m, 3H), 6.97 (d, J = 8.0 Hz, 2H), 3.03-2.74 (m, 5H), 2.48 (s, 3H), 1.91-1.73 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 164.3, 156.5, 150.3, 149.1, 139.6, 135.2, 134.8, 128.9, 128.4, 128.0, 127.9, 127.0, 126.4, 126.0, 125.9, 120.2, 47.7, 43.3, 35.4, 34.6, 26.4, 25.2 ppm; HRMS (ESI) calcd for C₂₇H₂₇N₂O₂ [M+H]⁺ 411.2067, found 411.2070.



2-(4-(*p***-Tolyl)undecyl)quinazolin-4(3H)-one (5b):** White solid (64.5 mg, 77% yield), m.p.:176.8-188.0 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.29 (brs, 1H), 8.24 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.4 Hz, 2H), 7.76 (t, J = 8.4 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.21 (d, J = 8.0 Hz, 2H), 2.81-2.73 (m, 2H), 2.69-2.61 (m, 1H), 2.50 (s, 3H), 1.85-1.61 (m, 5H), 1.58-1.50 (m, 1H), 1.24-1.04 (m, 10H), 0.81 (t, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 164.4, 156.6, 151.5, 149.4, 135.1, 134.8, 128.5, 127.8, 127.2, 126.3, 126.0, 120.3, 45.9, 36.6, 35.9, 35.7, 31.7, 29.5, 29.1, 27.4, 26.4, 25.4, 22.5, 14.0 ppm; HRMS (ESI) calcd for C₂₂H₃₅N₂O₂ [M+H]⁺ 419.2693, found 419.2700.



2-(4-(4-Acetylphenyl)-4-cyclopentylbutyl)quinazolin-4(3H)-one (5c): White solid (42.7 mg, 55% yield), m.p.:181.8-182.5 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 11.44 (brs, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 2H), 7.77 (t, J = 8.0 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.22 (d, J = 8.0 Hz, 2H), 2.78-2.63 (m, 2H), 2.51 (s, 3H), 2.42 (td, J = 10.4 Hz, 3.2 Hz, 1H), 2.01-1.87 (m, 3H), 1.79-1.71 (m, 1H), 1.66-1.57 (m, 3H), 1.56-1.46 (m, 2H), 1.42-1.35 (m, 1H), 1.30-1.19 (m, 2H), 0.96-0.88 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 163.9, 156.3, 151.2, 149.3, 135.2, 134.8, 128.4, 128.2, 127.2, 126.4, 126.1, 120.4, 52.1, 46.4, 35.8, 34.4, 31.6, 31.5, 26.5, 25.4, 25.1, 24.8 ppm; HRMS (ESI) calcd for C₂₅H₂₉N₂O₂ [M+H]⁺ 389.2224, found 389.2226.



2-(2-(1-(4-Acetylphenyl)ethoxy)ethyl)quinazolin-4(3H)-one (5d): White solid (59.8 mg, 89% yield), m.p.:185.5-187.5 °C; $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 11.24 (brs, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 2H), 7.75 (t, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H),

7.46 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 4.53 (q, J = 6.4 Hz, 1H), 3.84-3.75 (m, 2H), 3.01 (t, J = 6.4 Hz, 2H), 2.52 (s, 3H), 1.44 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.6, 162.9, 154.6, 149.0, 148.3, 136.5, 134.7, 128.6, 127.1, 126.5, 126.3, 126.2, 120.9, 78.4, 65.8, 36.1, 26.5, 23.7 ppm; **HRMS** (ESI) calcd for C₂₀H₂₁N₂O₃ [M+H]⁺ 337.1547, found 337.1545.



2-((3-(4-Acetylphenyl)cyclopentyl)methyl)quinazolin-4(3H)-one (5e): White solid (40.9 mg, 59% yield; d.r. = 1:1), m.p.:162.5-163.9 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.48 (brs, 1H), 8.29 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 2H), 7.78 (t, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.30-7.27(m, 2H), 3.36-3.28 (m, 0.5H), 3.18-3.09 (m, 0.5H), 2.99-2.69 (m, 3H), 2.54 (s, 1.5H), 2.53 (s, 1.5H), 2.34-1.91 (m, 4H), 1.81-1.51 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 164.5, 156.2, 152.2, 151.5, 149.5, 135.0, 134.9, 134.8, 128.4, 127.2, 127.14, 127.12, 126.4, 126.1, 120.4, 45.6, 44.2, 41.9, 41.7, 41.3, 39.6, 38.7, 37.9, 34.7, 33.1, 32.9, 31.6, 26.5 ppm; HRMS (ESI) calcd for C₂₂H₂₃N₂O₂ [M+H]⁺ 347.1754, found 347.1750.



2-((3-(4-Acetylphenyl)octahydropentalen-1-yl)methyl)quinazolin-4(3H)-one (5f): White solid (54.1 mg, 70% yield; d.r. = 1:1), m.p.:177.5-178.9 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.58 (brs, 1H), 8.30 (d, J = 8.0 Hz, 1H), 7.80-7.77 (m, 3H), 7.72 (d, J = 7.6 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 3.10 (m, 1H), 2.83 (m, 1H), 2.62-2.50 (m, 5H), 2.47-2.41 (m, 1H), 2.26-2.16 (m, 1H), 2.09-2.04 (m, 1H), 1.73-1.56 (m, 5H), 1.51-1.46 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 164.6, 156.3, 150.8, 149.5, 135.1, 134.8, 128.4, 127.4, 127.2, 126.4, 126.1, 120.3, 52.5, 52.2, 50.2, 46.0, 42.0, 41.2, 32.0, 26.5, 25.0 ppm; HRMS (ESI) calcd for C₂₅H₂₇N₂O₂ [M+H]⁺ 387.2067, found 387.2070.



Methyl

2-(4-(2-(4-acetylphenyl)-5-(4-oxo-3,4-dihydroquinazolin-2-

yl)pentyl)phenyl)propanoate (5g): White solid (70.5 mg, 71% yield), m.p.:187.0-188.5 °C; $R_f = 0.2$ (PE/EA = 3/1); ¹**H NMR** (400 MHz, CDCl₃) δ 11.91 (brs, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.78-7.76 (m, 3H), 7.69 (d, J = 8.4 Hz, 1H), 7.49-7.45 (m, 1H), 7.19 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 7.6 Hz, 2H), 3.69-3.59 (m, 4H), 3.00-2.92 (m, 1H), 2.90-2.81 (m, 2H), 2.78-2.70 (m, 2H), 2.49 (s, 3H), 1.89-1.71 (m, 4H), 1.42 (d, J = 7.2 Hz, 3H); ¹³**C NMR** (100 MHz, CDCl₃) δ 197.7, 175.0, 164.2, 156.6, 150.3, 138.6, 138.1, 135.3, 134.9, 129.2, 128.5, 127.9, 126.5, 126.1, 120.3, 51.9, 47.6, 44.9, 42.8, 35.4, 34.6, 26.4, 25.2, 18.5 ppm; **HRMS** (ESI) calcd for C₃₁H₃₃N₂O₄ [M+H]⁺ 497.2435, found 497.2436.



2-(4-(4-Acetylphenyl)pentyl)-3-methylquinazolin-4(3H)-one (5h): Colorless oil (62.6 mg, 91% yield), $R_f = 0.2$ (PE/EA = 5/1); ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.69-7.64 (m, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.40-7.36 (m, 1H), 7.27 (d, J = 8.4 Hz, 2H), 3.50 (s, 3H), 2.87-2.79 (m, 1H), 2.77-2.71 (m, 2H), 2.55 (s, 3H), 1.79-1.64 (m, 4H), 1.27 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 162.3, 156.5, 152.7, 147.0, 135.1, 133.9, 128.5, 127.1, 126.7, 126.5, 126.2, 120.0, 39.8, 37.3, 35.3, 30.2, 26.4, 24.6, 22.0 ppm; HRMS (ESI) calcd for C₂₂H₂₅N₂O₂ [M+H]⁺ 349.1911, found 349.1913.



2-(4-(4-Acetylphenyl)pentyl)-6-fluoroquinazolin-4(3H)-one (5i): White solid (46.5 mg, 66% yield), m.p.:177.3-178.5 °C; $R_f = 0.2$ (PE/EA = 4/1);.¹**H NMR** (400 MHz, CDCl₃) $\delta = 12.25$ (brs, 1H), 7.86-7.82 (m, 3H), 7.68 (dd, J = 9.2 Hz, 4.8 Hz, 1H), 7.49 (td, J = 8.0 Hz, 3.2 Hz, 1H), 7.26 (d, J = 8.0 Hz, 2H), 2.88-2.80 (m, 1H), 2.76 (t, J = 6.8 Hz, 2H), 2.52 (s, 3H), 1.89-1.73 (m, 4H), 1.28 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 163.8 (d, $J_{C-F} = 3.4$ Hz), 160.5 (d, $J_{C-F} = 246.7$ Hz), 155.8, 152.8, 146.1, 135.2, 129.6 (d, $J_{C-F} = 7.9$ Hz), 128.6, 127.1, 123.4 (d, $J_{C-F} = 23.9$ Hz), 121.4 (d, $J_{C-F} = 8.5$ Hz), 110.8 (d, $J_{C-F} = 23.5$ Hz), 39.8, 37.3, 35.5, 26.4, 25.3, 22.0 ppm; **HRMS** (ESI) calcd for C₂₁H₂₂FN₂O₂ [M+H]⁺ 353.1660, found 353.1662.



2-(4-(4-Acetylphenyl)pentyl)-6-methylquinazolin-4(3H)-one (5j): White solid (13.9 mg, 20% yield); m.p. = 186.4-187.9 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.18 (brs, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 2H), 7.47 (s, 1H), 7.28-7.24 (m, 3H), 2.85-2.75 (m, 3H), 2.51 (s, 3H), 2.49 (s, 3H), 1.86-1.75 (m, 4H), 1.26 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 164.3, 156.6, 152.9, 149.5, 145.8, 135.2, 128.6, 127.9, 127.1, 127.0, 125.9, 117.9, 39.8, 37.3, 35.6, 26.5, 25.4, 22.01, 21.96; HRMS (ESI) calcd for C₂₂H₂₅N₂O₂ [M+H]⁺ 349.1911, found 349.1920.



2-(4-(4-Acetylphenyl)pentyl)-7-chloroquinazolin-4(3H)-one (5k): White solid (55.3 mg, 75% yield), m.p. = 172.7-174.2 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 11.76 (brs, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 2.0 Hz, 1H), 7.41 (dd, J = 8.8 Hz, 2.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 2.86-2.81 (m, 1H), 2.74 (t, J = 6.8 Hz, 2H), 2.54 (s, 3H), 1.87-1.75 (m, 4H), 1.28 (d, J = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 163.5, 157.6, 152.8, 150.3, 141.1, 135.3, 128.6, 127.6, 127.2, 127.1, 126.9, 118.8, 39.8, 37.3, 35.6, 26.5, 25.2,
22.0 ppm; HRMS (ESI) calcd for C₂₁H₂₂ClN₂O₂ [M+H]⁺ 369.1364, found 369.1369.



2-(4-(4-Acetylphenyl)pentyl)-8-methylquinazolin-4(3H)-one (5I): White solid (45.3 mg, 65% yield), m.p. = 185.7-186.9 °C; $R_f = 0.2$ (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.28 (brs, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 2H), 7.48 (s, 1H), 7.29-7.24 (m, 3H), 2.85-2.77 (m, 3H), 2.52 (s, 3H), 2.49 (s, 3H), 1.90-1.74 (m, 4H), 1.26 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 164.3, 156.7, 152.9, 149.3, 145.9, 135.1, 128.5, 127.9, 127.1, 126.8, 125.8, 117.8, 39.7, 37.3, 35.5, 26.4, 25.4, 21.95, 21.91 ppm; HRMS (ESI) calcd for C₂₂H₂₅N₂O₂ [M+H]⁺ 349.1911, found 349.1912.



2-(3-(4-Acetylphenyl)propyl)quinazolin-4(3H)-one (5m): White solid (53.9 mg, 88% yield), m.p. = 176.1-177.9 °C; R_f = 0.2 (PE/EA = 4/1); ¹H NMR (400 MHz, CDCl₃) δ 12.28 (brs, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.79 (t, J = 8.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H) , 2.88-2.83 (m, 4H), 2.54 (s, 3H), 2.32-2.24 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 197.8, 164.5, 156.2, 149.4, 147.1, 135.1, 134.9, 128.7, 128.5, 127.2, 126.5, 126.1, 120.4, 35.3, 35.2, 28.4, 26.5 ppm; HRMS (ESI) calcd for C₁₉H₁₉N₂O₂ [M+H]⁺ 307.1441, found 307.1440.



2-(5-(4-Acetylphenyl)-5-phenoxypentyl)quinazolin-4(3H)-one (5n): Colorless oil (68.2 mg, 80% yield), $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.16 (brs, 1H), 8.07 (d, *J* = 8.4 Hz, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.78-7.73 (m, 1H), 7.56 (m, 1H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.46-7.42 (m, 1H), 7.19-7.15 (m, 2H), 6.87-6.81 (m, 3H), 5.41 (dd, *J* = 7.2 Hz, 5.2 Hz, 1H), 2.59 (t, *J* = 7.2 Hz, 2H), 2.52 (s, 3H), 2.01-1.92 (m, 1H), 1.86-1.74 (m, 3H), 1.55-1.34 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 197.9, 162.3, 158.0, 157.8, 149.4, 147.7, 136.5, 134.8, 129.9, 128.9, 127.3, 126.9, 126.4, 126.2, 121.3, 121.2, 116.2, 78.4, 37.7, 34.8, 27.2, 27.0, 25.1 ppm; HRMS (ESI) calcd for C₂₇H₂₇N₂O₃ [M+H]⁺ 427.2016, found 427.2015.



2-(4-(3-Oxo-1,3-dihydroisobenzofuran-5-yl)pentyl)quinazolin-4(3H)-one (6a): White solid (55.4 mg, 86% yield), m.p. = 190.5-192.1 °C; $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 11.57 (brs, 1H), 8.25 (d, J = 7.6 Hz, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.77-7.73 (m, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 4.62 (s, 2H), 3.98 (t, J = 6.0 Hz, 2H), 3.09 (t, J = 6.0 Hz, 2H), 2.52 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 163.2, 154.6, 149.0,

142.9, 136.4, 134.7, 128.5, 127.4, 127.1, 126.5, 126.3, 120.8, 72.5, 67.4, 36.0, 26.6 ppm; **HRMS** (ESI) calcd for C₁₉H₁₉N₂O₃ [M+H]⁺ 323.1390, found 323.1388.



Benzyl (4-acetylbenzyl)(2-(4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (6b): Colorless oil (67.4 mg, 74% yield), $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 12.14 (brs, 1H), 8.22-8.14 (m, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.77-7.74 (m, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.46-7.42 (m, 1H), 7.33-7.22 (m, 7H), 5.15 (s, 2H), 4.65 (s, 2H), 3.87 (t, J = 6.8 Hz, 2H), 3.12-3.01 (m, 2H), 2.53 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 197.5, 153.9, 143.2, 136.2, 134.8, 130.9, 128.6, 128.5, 128.1, 127.8, 127.7, 127.2, 126.9, 126.6, 126.2, 120.4, 67.6, 51.2, 44.6, 37.8, 26.6 ppm; HRMS (ESI) calcd for C₂₇H₂₆N₃O₄ [M+H]⁺ 456.1918, found 456.1919.



2-(3-((4-Acetylbenzyl)oxy)propyl)quinazolin-4(3H)-one (6c): White solid (48.4 mg, 72% yield), m.p. = 188.6-189.9 °C; R_f = 0.2 (PE/EA = 2/1); ¹**H NMR** (400 MHz, CDCl₃) δ 11.71 (brs, 1H), 8.23 (d, *J* = 8.0 Hz, 1H), 7.87 (d, *J* = 8.0 Hz, 2H), 7.76 (t, *J* = 8.4 Hz, 1H), 7.68 (d, *J* = 8.0 Hz, 1H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 2H), 4.59 (s, 2H), 3.67 (t, *J* = 6.0 Hz, 2H), 2.93 (t, *J* = 7.2 Hz, 2H), 2.56 (s, 3H), 2.26-2.19 (m, 2H); ¹³**C NMR** (100 MHz, CDCl₃) δ 197.8, 163.9, 156.3, 149.3, 143.6, 136.3, 134.7, 128.4, 127.3, 127.1, 126.4, 126.2, 120.5, 72.2, 69.6, 32.8, 27.1, 26.6 ppm; **HRMS** (ESI) calcd for C₂₀H₂₁N₂O₃ [M+H]⁺ 337.1547, found 337.1545.



Benzyl (4-acetylbenzyl)(3-(4-oxo-3,4-dihydroquinazolin-2-yl)propyl)carbamate (6d): Colorless oil (61.0 mg, 65% yield); $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 12.19 (brs, 0.4H), 12.09 (brs, 0.5H), 8.26 (d, J = 7.6 Hz, 1H), 7.84 (d, J = 8.0 Hz, 2H), 7.79-7.71 (m, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.43 (t, J = 7.2 Hz, 1H), 7.33-7.23 (m, 7H), 5.19 (s, 0.9H), 5.14 (s, 1.1H), 4.65 (s, 0.9H), 4.59 (s, 1.1H), 3.51-3.40 (m, 2H), 2.81-2.70 (m, 2H), 2.55 (s, 3H), 2.18-2.11 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 197.6, 164.3, 163.8, 156.6, 156.5, 156.0, 155.6, 149.2, 143.1, 143.0, 136.4, 136.2, 136.1, 134.8, 134.7, 128.6, 128.4, 128.0, 127.8, 127.7, 127.1, 127.0, 126.5, 126.4, 126.2, 120.5, 120.4, 67.5, 67.4, 50.2, 49.9, 46.3, 45.7, 32.5, 32.4, 26.5, 25.3 ppm; a mixture of amide rotamers; HRMS (ESI) calcd for C₂₈H₂₈N₃O₄ [M+H]⁺ 470.2074, found 470.2080.

2-(2-(4-Phenylbutoxy)ethyl)quinazolin-4(3H)-one (6e): White solid (43.1 mg, 67% yield), m.p. = 183.1-185.0 °C; $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 10.36 (brs, 1H), 8.27 (d, J = 8.0 Hz, 1H), 7.76-7.72 (m, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.47-7.43 (m, 1H), 7.28-7.24 (m, 2H), 7.18-7.16 (m, 3H), 3.82 (t, J = 6.0 Hz, 2H), 3.54 (t, J = 6.4 Hz, 2H), 2.99 (t, J = 5.6 Hz, 2H), 2.64 (t, J = 6.8 Hz, 2H), 1.74-1.66 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 162.1, 155.1, 148.8, 142.1, 134.6, 128.4, 128.3, 127.0, 126.5, 126.4, 125.7, 121.2, 71.5, 67.6, 35.9, 35.5, 29.0, 27.8 ppm;

HRMS (ESI) calcd for $C_{20}H_{23}N_2O_2$ [M+H]⁺ 323.1754, found 323.1760.



5-(2-(4-Oxo-3,4-dihydroquinazolin-2-yl)ethoxy)pentanenitrile (6f): White solid (27.1 mg, 50% yield), m.p. = 190.5-191.7 °C; $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 11.21 (brs, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.77-7.73 (m, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.48-7.44 (m, 1H), 3.90 (t, J = 6.0 Hz, 2H), 3.56 (t, J = 6.0 Hz, 2H), 3.03 (t, J = 6.0 Hz, 2H), 2.33 (t, J = 6.8 Hz, 2H), 1.77-1.69 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 163.0, 154.7, 148.9, 134.7, 127.0, 126.5, 126.2, 120.8, 119.5, 70.0, 67.7, 35.8, 28.3, 22.3, 16.8 ppm; HRMS (ESI) calcd for C₁₅H₁₈N₃O₂ [M+H]⁺ 272.1394, found 272.1400.



2-(2-(Pent-4-yn-1-yloxy)ethyl)quinazolin-4(3H)-one (6g): White solid (26.6 mg, 52% yield), m.p. = 177.7-179.3 °C; $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 10.90 (brs, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.76-7.72 (m, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.47-7.43 (m, 1H), 3.89 (t, J = 6.0 Hz, 2H), 3.63 (t, J = 6.4 Hz, 2H), 3.03 (t, J = 6.0 Hz, 2H), 2.28 (td, J = 6.8 Hz, 2.4 Hz, 2H), 1.92 (t, J = 2.4 Hz, 1H), 1.85-1.78 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 154.8, 148.9, 134.6, 127.0, 126.5, 126.3, 120.9, 83.5, 69.7, 68.8, 67.8, 35.9, 28.2, 15.1 ppm; HRMS (ESI) calcd for C₁₅H₁₇N₂O₂ [M+H]⁺ 257.1285, found 257.1288.



2-(2-(Pent-4-en-1-yloxy)ethyl)quinazolin-4(3H)-one (6h): White solid (23.2 mg, 45% yield); m.p. = 173.9-175.1 °C; $R_f = 0.2$ (PE/EA = 2/1); ¹H NMR (400 MHz, CDCl₃) δ 10.53 (brs, 1H), 8.27 (d, J = 8.4 Hz, 1H), 7.76-7.72 (m, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.47-7.43 (m, 1H), 5.84-5.74 (m, 1H), 5.05-4.94 (m, 2H), 3.85 (t, J = 5.6 Hz, 2H), 3.54 (t, J = 6.8 Hz, 2H), 3.01 (t, J = 6.0 Hz, 2H), 2.14 (q, J = 7.2 Hz, 2H), 1.77-1.70 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 162.2, 155.1, 148.9, 137.8, 134.6, 127.0, 126.5, 126.4, 121.1, 115.1, 70.9, 67.6, 35.9, 30.2, 28.6 ppm; HRMS (ESI) calcd for C₁₅H₁₉N₂O₂ [M+H]⁺ 259.1441, found 259.1443.



2-(4-(2-(4-Oxo-3,4-dihydroquinazolin-2-yl)ethoxy)butyl)isoindoline-1,3-dione (6i): White solid (43.1 mg, 55% yield), m.p. = 193.0-194.5 °C; $R_f = 0.2$ (PE/EA = 1:1); ¹H NMR (400 MHz, CDCl₃) δ 10.56 (brs, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.84-7.80 (m, 2H), 7.73-7.68 (m, 3H), 7.64 (d, J = 8.0 Hz, 1H), 7.44-7.40 (m, 1H), 3.86 (t, J = 6.0 Hz, 2H), 3.71 (t, J = 6.8 Hz, 2H), 3.57 (t, J = 6.4 Hz, 2H), 3.01 (t, J = 6.0 Hz, 2H), 1.81-1.73 (m, 2H), 1.70-1.63 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 168.4, 162.2, 155.0, 148.7, 134.5, 133.9, 132.0, 126.9, 126.5, 126.4, 123.2, 121.1, 70.8, 67.8, 37.5, 35.9, 26.5, 25.3 ppm; HRMS (ESI) calcd for C₂₂H₂₂N₃O4 [M+H]⁺ 392.1605, found 392.1607.

10. References

1. (a) Y.-L. Luo, Y. Wu, Y.-Y. Wang, H.-M. Sun, Z.-Y. Xie, W.-Q. Zhang and Z.-W. Gao, *RSC Adv.* 2016, **6**, 66074; (b) X.-Y. Lv, R. Abrams and R. Martin, *Nat. Commun.* 2022, **13**, 2394.

2. M. R. Mutra and J.-J. Wang, Nat. Commun. 2022, 13, 2345.

3. (a) U. Jakob, S. Mundinger and W. Bannwarth, *Eur. J. Org. Chem.* 2014, 6963; (b) N. Radhoff and A. Studer, *Nat. Commun.* 2022, **13**, 3083.

4. J. Luo, X. Zhang, J.-Z. Lu and J. Zhang, ACS Catal. 2017, 7, 5062.

(a) J. M. L. Elwood, M. C. Henry, J. D. Lopez-Fernandez, J. M. Mowat, M. Boyle, B. Buist, K. Livingstone and C. Jamieson, *Org. Lett.* 2022, 24, 9491; (b) X.-Y. Yao, Z.-Y. Li, H.-B. Mei, J. Escorihuela, V. A. Soloshonok and J.-L. Han, *J. Org. Chem.* 2023, 88, 13057; (c) Z.-L. Shen, X.-F. He, Y.-M. Hong, X.-Q. Hu, W.-M. Mo, B.-X. Hu and N. Sun, *Synth. Commun.* 2011, 41, 3644; (d) F. A. Cabrera-Rivera, C. Ortíz-Nava, P. Román-Bravo and M. A. Leyva, J. Escalante, 2012, 85, 2173.
L. Marie Kammer, S. O. Badir, R.-M. Hu and G. A. Molander, *Chem. Sci.* 2021, 12, 5450.

11. ¹H NMR and ¹³C NMR Spectra of Materials and Products

¹H NMR (400 MHz, DMSO- d_6) and ¹³C NMR (100 MHz, DMSO- d_6 spectra of product **1a**



¹H NMR (400 MHz, DMSO- d_6) and ¹³C NMR (100 MHz, DMSO- d_6 spectra of product **1b**















f1 (ppm) 00 190





¹H NMR (400 MHz, DMSO-*d*₆) and ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of product **1i**



¹H NMR (400 MHz, DMSO-*d*₆) and ¹³C NMR (100 MHz, DMSO-*d*₆) spectra of product **1**j















¹H NMR (400 MHz, DMSO- d_6) and ¹³C NMR (100 MHz, DMSO- d_6) spectra of product **1n**





¹H NMR (400 MHz, DMSO- d_6) and ¹³C NMR (100 MHz, DMSO- d_6) spectra of product **10**





S57





9. Characterization of Products

¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **3a**













¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **3d**



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **3e**

 ^1H NMR (400 MHz, CDCl₃), ^{19}F NMR (376 MHz, CDCl₃) and ^{13}C NMR (100 MHz, CDCl₃) spectra of product **3f**















3.0 12.5 12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 11(ppm)






























¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **3r**



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **3s**











7.0 6.5 6.0 f1 (ppm) 5.5

5.0 4.5 4.0 3.5

7.5

2.0

1.5 1.0 0.5

3.0 2.5

3.0 12.5 12.0 11.5

11.0 10.5 10.0 9.5 9.0 8.5 8.0









¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **3y**





¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 5a











 ^1H NMR (400 MHz, CDCl₃) and ^{13}C NMR (100 MHz, CDCl₃) spectra of product **5d**



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **5**e



 $\begin{array}{c} 8.212\\ 8.192\\ 7.769\\ 7.785\\ 7.785\\ 7.785\\ 7.765\\ 7.765\\ 7.765\\ 7.765\\ 7.765\\ 7.765\\ 7.765\\ 7.765\\ 7.765\\ 7.705\\ 7.$







S92





















S98



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 6a



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **6b**



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 6c



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 6d







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 6f



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **6g**







¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 7a


¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 8a



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **9a**



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product 10a



¹H NMR (400 MHz, CDCl₃) and ¹³C NMR (100 MHz, CDCl₃) spectra of product **11a**



